(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 January 2002 (10.01.2002)

PCT

(10) International Publication Number
WO 02/02630 A2

(51) International Patent Classification[7]: C07K 14/705

(21) International Application Number: PCT/GB01/02959

(22) International Filing Date: 3 July 2001 (03.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0016360.0 3 July 2000 (03.07.2000) GB
0026946.4 3 November 2000 (03.11.2000) GB

(71) Applicant (*for all designated States except US*): **SMITHKLINE BEECHAM P.L.C.** [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): **STRIJBOS, Paul, Johannes, Leonardus, Maria** [NL/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **BATES, Stewart** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **GLOGER, Isro** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **DAVIES, Ceri** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB).

(74) Agent: **CONNELL, Anthony, Christopher**; Corporate Intellectual Property, SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/02630 A2

(54) **Title:** NEW USE

(57) **Abstract:** The invention relates to newly identified uses of HCN channel polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

New Use

The present invention relates to newly identified uses of human hyperpolarisation-activated, cyclic nucleotide-gated (HCN) channel polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds, which may be agonists or antagonists, which are potentially useful in therapy. The invention further relates to newly identified HCN polypeptides and polynucleotides.

Hyperpolarisation-activated cation currents or anomalous rectifier currents, most commonly referred to as I_h (and alternatively referred to as I_Q or I_f) (Halliwell & Adams (1982) Brain Res 250 71-92; Mayer & Westbrook (1983) J.Physiol. 340, 19-45; DiFrancesco et al (1986) J.Physiol. 377, 61-88; Spain et al (1987) J. Neurophysiol. 57, 1555-1576; McCormick & Pape (1990) J.Physiol. 431, 319-342; Maccaferri et al (1993) J. Neurophysiol. 69, 2129-2136), were originally observed in heart where they have been shown to be important in the pacemaking activity underlying rhythmical heart beat. Since then it has become increasingly clear that tissues and organs other than heart also express I_h, including smooth muscle, endothelium and both inhibitory and excitatory neurons of the central nervous system. As with other ion channels, I_h displays specialized biophysical properties that are specifically suited to the physiological roles it plays throughout the body. Thus, I_h is inactive at depolarized membrane potentials, where action potentials are firing, but is turned on by hyperpolarization such that at membrane potentials more negative than –50 mV I_h is activated and passes cations into the cell causing a slow depolarization that deactivates upon continued depolarization. These particular characteristics arise from the specialized structural features of the ion channel subunits that generate the I_h current. In particular, the I_h current appears to be mediated by a new family of ion channels termed hyperpolarisation-activated cyclic nucleotide-gated (HCN) channels. These channels form a sub-family of the superfamily of voltage-gated cation channels and to date, the primary sequences of four cDNAs encoding mammalian HCN channels have been cloned, as well as a cDNA encoding an HCN channel from sea urchin sperm. Structural analysis of these channels identifies HCN channels as cousins of voltage gated K^+ channels that display properties of cyclic nucleotide gated non-selective channels, the plant inwardly rectifying K^+ channel KAT1 and the mammalian HERG K^+ channels. In particular, HCN channel subunits contain six transmembrane helices (S1-S6), an ion-conducting P region between the fifth and sixth segment and a cyclic nucleotide binding domain in the C-terminus. The amino acid sequences of HCN1-4 have an overall identity of about 60% across the coding region, with up to 90% identity across the transmembrane domains and cyclic nucleotide-binding pocket. Electrophysiological analysis has

revealed that HCN channels are non-selective cation channels that are permeable to both sodium and potassium ions. They possess a relatively small single channel conductance (around 1 pS in heart) and are inhibited, in a non use-dependent manner, by extracellular Cs^+ concentrations in the 0.1-1 mM range or N-ethyl-1,6-dihydro-1,2-dimethyl-6-(methylimino)-N-phenyl-4-
5 pyrimidinamine hydrochloride (ZD7288) in the 1-300 μM range (Bosmith et al (1993) Br. J. Pharmacol. 110, 343-; Harris & Constanti, (1995) J. Neurophysiol. 74, 2366-2378; Gasparini & DiFrancesco (1997) Pflügers Arch 435, 99-106). Binding of cyclic nucleotides to the cyclic nucleotide binding pocket most commonly results in a depolarizing shift in the steady state activation curve of I_h and possession of this binding pocket enables wide ranging transmitter
10 systems to modulate the activity of this current (DiFrancesco et al (1986) supra; Bobker & Williams (1989) Neuron 2, 1530-1540; McCormick & Pape (1990) supra; DiFrancesco (1991) J. Physiol. 434, 23-40; Banks et al (1993) J. Neurophysiol. 70, 1420-1432; Jiang et al (1993) J. Physiol. 450, 455-468; Travagli & Gillis (1994) J. Neurophysiol. 71, 1308-1317; Ingram & Williams (1994) Neuron 13, 179-186). Thus, for example, activation of β-adrenergic receptors in
15 the heart stimulates adenylyl cyclase activity which raises cAMP levels which, in turn, increases I_h activity and accelerates membrane depolarization. This, combined with other effects of β-adrenergic receptor activation, can result in a doubling in cardiac cell firing rate. Whilst the heart provides a clear illustration of one of the physiological functions fulfilled by HCN channels, activation of these channels, and modification of their activity by cellular processes that regulate
20 cAMP production (e.g. via activation of G protein coupled receptors), in other regions of the body are likely to be equally important in determining the mental and physical well-being of an individual. In this respect, activation of HCN channels and generation of I_h has been shown to be critically involved in 1) determining neuronal resting membrane potentials, 2) regulating the response of neurons to hyperpolarising currents, 3) generating 'pacemaker' potentials that control
25 the rate of rhythmic oscillations and 4) modulating calcium-independent neurotransmitter release; cellular processes that are critical for physiological functions such as sleep cycles, cognition and hormone secretion. Interestingly, whilst most of these physiological functions are likely to result from the electrophysiological characteristics of HCN channels it has recently been suggested that these channels may produce some of their actions by non-electrophysiological interactions with
30 intracellular processes (e.g. microtubule and actin transport systems). As such, HCN channels exhibit highly diverse functions at the molecular, cellular and physiological levels and provide a useful target for therapeutic intervention in the treatment of human diseases relating to peripheral or CNS dysfunction. One area of interest is stroke where inhibitors of HCN function may reduce the neuronal overexcitability that initiates neurodegeneration by inhibiting glutamate release and
35 reducing the probability of action potential firing. Conversely, activators of HCN channel

function may also be neuroprotective since activation of HCN channels in inhibitory circuits may potentially counterbalance the increased activity in excitatory circuits observed during neurodegenerative insults.

The present invention is based on the finding that blocking the activation of HCN
5 channels confers protection against neuronal cell death in organotypic hippocampal slice cultures subjected to oxygen and glucose deprivation, as well as in dispersed primary hippocampal neurons subjected to excitotoxicity. Further, the HCN channels, in particular the HCN1 and HCN4 channels, have been shown to be upregulated in a mouse model of stroke (permanent middle cerebral artery occlusion model). These two lines of evidence show that HCN channels
10 are strong candidates for targets for therapeutic intervention for the prevention and/ or treatment of diseases such as stroke, epilepsy, ischaemia, head injury, Alzheimer's disease, and also learning, memory and attention disorders. Neuroprotection is a major therapeutic target of the pharmaceutical industry and there is a clear need for the development of effective treatments for this important therapeutic goal.

15 Further, HCN channels are potential targets for therapeutic intervention for the treatment of pain, gut disorders, in particular Irritable Bowel Syndrome (IBS) and sleep disorders.

Thus the present invention provides for the use of a compound selected from:

(a) a HCN channel polypeptide, or a fragment thereof;

20 (b) a compound which inhibits an HCN channel polypeptide;

(c) a compound which activates an HCN channel polypeptide; or

(d) a polynucleotide capable of inhibiting the expression of an HCN channel polypeptide,

for the manufacture of a medicament for treating, stroke, ischaemia, head injury, epilepsy,
25 Alzheimer's disease, Parkinson's disease, learning or memory and attention disorders.

The present invention also provides for the use of a compound selected from:

(a) an HCN channel polypeptide, or a fragment thereof;

(b) a compound which inhibits an HCN channel polypeptide;

(c) a compound which activates an HCN channel polypeptide; or

30 (d) a polynucleotide capable of inhibiting the expression of an HCN channel polypeptide,

for the manufacture of a medicament for treating pain, migraine, gut disorders, in particular IBS, or sleep disorders.

The invention also relates to newly identified HCN1 polypeptides and polynucleotides. A
35 partial HCN1 channel has previously been published (GenBank Accession number AF064876;

Santoro et al PNAS (1997) 94(26) pp14815-20). However a full-length human HCN1 polynucleotide sequence is given hereinbelow as SEQ ID NO:1 and the encoded polypeptide sequence as SEQ ID NO:2. The invention further relates to uses of these new polypeptides and polynucleotides.

In a first aspect, the present invention relates to the use of an HCN channel polypeptide for the manufacture of a medicament for treating, stroke, ischaemia, head injury, epilepsy, Alzheimer's disease, Parkinson's disease, learning or memory and attention disorders, pain, migraine, gut disorders, in particular IBS, or sleep disorders. Preferably such polypeptides include a human HCN channel polypeptide, in particular:

a) an isolated HCN1 polypeptide comprising an amino acid sequence having at least 95% identity to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2;

b) an isolated HCN2 polypeptide comprising an amino acid sequence having at least 95% identity to that of SEQ ID NO:4, over the entire length of SEQ ID NO:4, where SEQ ID NO:4 is the sequence disclosed in GenBank Accession No: CAB42602;

c) an isolated HCN3 polypeptide characterised in that said polypeptide comprises a sequence that has at least 95% identity with the partial HCN3 sequence of SEQ ID NO:8, over the entire length of SEQ ID NO:8, where SEQ ID NO:8 is the sequence disclosed in GenBank Accession No: BAA96059; and

d) an isolated HCN4 polypeptide comprising an amino acid sequence having at least 95% identity to that of SEQ ID NO:6, over the entire length of SEQ ID NO:6, where SEQ ID NO:6 is the sequence disclosed in GenBank Accession No: CAB52754.

Such polypeptides include those comprising polypeptides having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 as well as the polypeptides of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8.

In addition the HCN polypeptides of the invention include variants and fragments and portions of such polypeptides in (a) to (d) that generally contain at least 30 amino acids, more preferably at least 50 amino acids, thereof..

Preferably the polypeptides of the invention are HCN1 or HCN4 polypeptides, as defined hereinabove, or fragments thereof, most preferably HCN1 polypeptides or fragments thereof..

The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The present invention also includes include variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; 5 and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, 10 synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

In a second aspect, the present invention relates to the use of an HCN channel polynucleotide for the manufacture of a medicament for treating, stroke, ischaemia, head injury, epilepsy, 15 Alzheimer's disease, Parkinson's disease, learning or memory and attention disorders, pain, migraine, gut disorders, in particular IBS, or sleep disorders. Preferably such polynucleotides include a human HCN channel polynucleotide, in particular:

a) an isolated HCN1 polynucleotide comprising a polynucleotide sequence having at least 95% identity to that of SEQ ID NO:1 over the entire length of SEQ ID NO:1;

20 b) an isolated HCN2 polynucleotide comprising a polynucleotide sequence having at least 95% identity to that of SEQ ID NO:3 over the entire length of SEQ ID NO:3, where SEQ ID NO:3 is the sequence disclosed in GenBank Accession No: AJ012582;

c) an isolated HCN3 polynucleotide characterised in that said polynucleotide comprises a sequence that has at least 95% identity with the partial HCN3 polynucleotide sequence of SEQ ID 25 NO:7, over the entire length of SEQ ID NO:7, where SEQ ID NO:7 is disclosed in GenBank Accession No: AB040968; and

d) an isolated HCN4 polynucleotide comprising a polynucleotide sequence having at least 95% identity to that of SEQ ID NO:5, over the entire length of SEQ ID NO:5, where SEQ ID NO:5 is the sequence disclosed in GenBank Accession No: AJ238850.

30 Such polynucleotides include those comprising polynucleotides having the sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7 as well as the polynucleotides of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 and SEQ ID NO:7.

The polynucleotide sequences encoding the polypeptides of SEQ ID NO:2, SEQ ID NO:4 SEQ ID NO:6, or SEQ ID NO:8 may be identical to the polypeptide encoding sequences contained 35 in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7 respectively, or they may be

sequences which, as a result of the redundancy (degeneracy) of the genetic code, also encode the aforesaid polypeptides.

In addition the HCN polynucleotides of the invention include variants and fragments and portions of such polynucleotides in (a) to (d) that generally contain at least 50 nucleotides, more
5 preferably at least 100 nucleotides, thereof.

Preferably the polynucleotides of the invention are HCN1 or HCN4 polynucleotides, as defined hereinabove, or fragments thereof, most preferably HCN1 polynucleotides or fragments thereof.

Polypeptides and polynucleotides of the present invention are herein understood to include any splice variant of the HCN channels.

10 HCN channel polynucleotides of the present invention may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human whole brain using techniques well established in the art (for example Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.(1989). Polynucleotides of the invention can also be obtained from natural sources
15 such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

Recombinant HCN channel polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression vectors
20 comprising HCN channel encoding polynucleotides. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Methods for expressing recombinant polypeptides are well known in the art, for example Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
25 (1989). When the HCN polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay.

In a further aspect, the present invention relates to the use of compounds which activate
30 (agonists) or inhibit (antagonists) HCN polypeptides for the manufacture of a medicament for treating stroke, ischaemia, head injury, epilepsy, Alzheimer's disease, Parkinson's disease, learning or memory and attention disorders, pain, migraine, gut disorders, in particular IBS, or sleep disorders. Such compounds can be identified using screens involving HCN polypeptides. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations,
35 chemical libraries, and natural product mixtures. Such agonists or antagonists so-identified may be

natural or modified HCN ligands or fragments of HCN channels etc. or may be structural or functional mimetics thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)).

Preferably the compounds activate or inhibit HCN1 or HCN4 polypeptides, most preferably HCN1 polypeptides.

In one embodiment the screening method involves the stable transfection of a standard cell line (e.g. human embryonic kidney cells, HEK293) with an HCN channel cDNA. Thereafter, cells may be loaded with a fluorescent membrane potential dye (e.g. DiBAC, Denyer et al, 1998, 3 Drug Discovery Today; Molecular Probes, USA), and exposed to valinomycin (Molecular Probes, USA) to allow membrane hyperpolaristion by potassium extrusion and subsequent activation of hHCN1. The occurrence of I_h, through activation of HCN, can be readily detected by fluorescent analysis of the cells by standard imaging techniques.

In a further embodiment the screening method involves stable transfection of a standard cell line (e.g. HEK293) with an HCN1 cDNA, as well as the inward rectifying potassium channel GIRK. Thereafter, cells may be loaded with a fluorescent membrane potential dye (e.g. DiBAC, Denyer et al, 1998, 3 Drug Discovery Today; Molecular Probes, USA), and exposed to a G protein coupled receptor (GPCR) agonist to activate endogenous GPCRs (e.g., somatostatin receptors,) or stably transfected GPCRs. Stimulation of these GPCRs will activate GIRK to allow membrane hyperpolaristion by potassium extrusion and subsequent activation of HCN. The occurrence of I_h, through activation of HCN, can be readily detected by fluorescent analysis of the cells by standard imaging techniques.

In a still further embodiment the screening method involves the use of radiotracer assays (e.g. ^{3}H-Choline, ^{14}C-Guanidinium, $^{22}Na^{+}$).

In another embodiment the screening method involves the use of the Intrinsic Ion Channel Fluorescence approach (Siegel et al (1998) Neuron 19, 735-741).

In a further embodiment the screening of putative HCN channel inhibitors involves adding the compound during the fluorescent dye loading, and assessing the changes in membrane potential following addition of either valinomycin, or a GPCR agonist (e.g., somatostatin), in the presence or absence of the putative HCN channel inhibitor.

In a still further embodiment, the putative HCN channel inhibitors are identified by measuring the binding of a candidate compound to the HCN channel transfected cells or membranes bearing the channel, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method involves competition with a labeled competitor. Such labeled competitors include known HCN channel antagonists, for example ZD7288 (Tocris, UK). Further, these screening methods may test

whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known activator (e.g., an agent that causes membrane hyperpolarization as described above) and the effect on activation by the activator by the presence of the candidate compound is observed. Constitutively active polpypeptides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide. Fusion proteins, such as those made from Fc portion and HCN channel polypeptide, as herein before described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett et al., J Mol Recognition, 8:52-58 (1995); and K. Johanson et al., J Biol Chem, 270(16):9459-9471 (1995)).

The polynucleotides, polypeptides of the present invention, as well as antibodies to the polypeptides of the present invention, which may be prepared usign methods well known in the art, may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agonists or antagonists from suitably manipulated cells or tissues.

Examples of potential polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or small molecules which bind to the polypetide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

It will be readily appreciated by the skilled artisan that an HCN polypeptide as defined hereinabove may also be used in a method for the structure-based design of a agonist or antagonist of the HCN channel polypeptide, by:

(a) determining in the first instance the three-dimensional structure of the HCN polypeptide;

(b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist or antagonist;

(c) synthesing candidate compounds that are predicted to bind to or react with the deduced binding or reactive site; and

(d) testing whether the candidate compounds are indeed agonists or antagonists.

It will be further appreciated that this will normally be an iterative process.

In a further aspect, the present invention provides methods of treating abnormal conditions related to an excess of HCN channel polypeptide activity such as, for instance, stroke, ischaemia,

head injury, Alzheimer's disease, Parkinson's disease, learning or memory and attention disorders. Further the invention the provides methods of treating abnormal conditions related to an excess of HCN channel polypeptide activity such as, for instance, pain, migraine, gut disorders, in particular IBS or sleep disorders. Preferably the abnormal condition is stroke, epilepsy, Alzheimer's disease, pain or migraine.

If the disease is associated with an increased or excessive activity of the HCN polypeptide several approaches are available. One approach comprises administering to a subject in need thereof an antagonist as herein above described, optionally in combination with a pharmaceutically acceptable carrier, in an amount effective to inhibit the function of the polypeptide, such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition. In another approach, soluble forms of the polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous polypeptide may be administered. Typical examples of such competitors include fragments of the HCN channel polypeptide.

In still another approach, expression of the gene encoding endogenous HCN channel polypeptide can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or externally administered (see, for example, O'Connor, J Neurochem (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Alternatively, oligonucleotides which form triple helices ("triplexes") with the gene can be supplied (see, for example, Lee *et al.,* Nucleic Acids Res (1979) 6:3073; Cooney *et al.,* Science (1988) 241:456; Dervan *et al.*, Science (1991) 251:1360). These oligomers can be administered *per se* or the relevant oligomers can be expressed *in vivo*. Synthetic antisense or triplex oligonucleotides may comprise modified bases or modified backbones. Examples of the latter include methylphosphonate, phosphorothioate or peptide nucleic acid backbones. Such backbones are incorporated in the antisense or triplex oligonucleotide in order to provide protection from degradation by nucleases and are well known in the art. Antisense and triplex molecules synthesised with these or other modified backbones also form part of the present invention.

In addition, expression of the human HCN channel polypeptide may be prevented by using ribozymes specific to the human HCN channel mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, et al., Curr. Opin. Struct. Biol (1996) 6(4), 527-33.) Synthetic ribozymes can be designed to specifically cleave HCN mRNAs at selected positions thereby preventing translation of the human HCN channel mRNAs into functional polypeptide. Ribozymes may be synthesised with a natural ribose phosphate backbone and natural bases, as normally found in RNA molecules.

Alternatively the ribosymes may be synthesised with non-natural backbones to provide protection from ribonuclease degradation, for example, 2'-O-methyl RNA, and may contain modified bases.

For treating abnormal conditions or diseases related to an under-expression of the HCN channel of the invention and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates an HCN channel polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of the HCN channel by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo*. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable pharmaceutical carrier.

The medicaments for use in treating the diseases mentioned hereinabove are pharmaceutical compositions comprising a therapeutically effective amount of a polypeptide, such as the soluble form of an HCN polypeptide, antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated

formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like.

The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 µg/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

The invention further relates to an isolated HCN1 polypeptide selected from the group consisting of:

(a) an isolated polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO:1;

(b) an isolated polypeptide comprising a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

(c) an isolated polypeptide having at least 95% identity to the polypeptide sequence of SEQ ID NO:2; and

(d) fragments and variants of such polypeptides in (a) to (c). In a preferred embodiment the invention relates to a polypeptide comprising the polypeptide sequence of SEQ ID NO:2. In a most preferred embodiment the polypeptide is the polypeptide of SEQ IDS NO:2.

The invention also relates to an isolated polynucleotide selected from the group consisting of:

(a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO:1;

(b) an isolated polynucleotide having at least 95% identity to the polynucleotide of SEQ ID NO:1;

(c) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

(d) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

(e) an isolated polynucleotide with a nucleotide sequence of at least 100 nucleotides obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof having at least 15 nucleotides;

(f) a polynucleotide which is the RNA equivalent of a polynucleotide of (a) to (e);

or a polynucleotide sequence complementary to said isolated polynucleotide
and polynucleotides that are variants and fragments of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.
Preferably the isolated polynucleotide is selected from the group consisiting of

5 (a) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1;
(b) the isolated polynucleotide of SEQ ID NO:1;
(c) an isolated polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2; and
(d) an isolated polynucleotide encoding the polypeptide of SEQ ID NO:2.

10 Isolated HCN1 polynucleotides of the present invention can be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA in cells of human brain (see for instance, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using 15 well known and commercially available techniques. Using techniques well know in the art (eg. Sambrook et al supra) the HCN1 polynucleotides can be used for the recombinant production of the polypeptides of the present invention.

Isolated HCN1 polypeptides of the present invention can also be used to devise screens for agonist and antagonist compounds for the treatment of one or more of the diseases mentioned 20 hereinabove. Examples of such screens are outlined hereinabove.

The invention also relates to the use of HCN polynucleotides and polypeptides as diagnostic reagents. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7 which is associated with a dysfunction or 25 disease mentioned hereinabove, in particular epilepsy, stroke, Alzheimer's disease, pain or migraine, will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

30 Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be 35 identified by hybridizing amplified DNA to labelled HCN polynucleotide sequences. Perfectly

matched sequences can be distinguished from mismatched duplexes by RNAse digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (ee, e.g., Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as Rnase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401). In another embodiment, an array of oligonucleotides probes comprising HCN polynucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee et al., Science, Vol 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to the diseases mentioned hereinabove, in particular epilepsy, stroke, Alzheimer's disease, pain or migraine, through detection of mutation in one or more HCN genes by the methods described. In addition, such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, Rnase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagonostic kit which comprises:
(a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7 or a fragment thereof ;
(b) a nucleotide sequence complementary to that of (a);
(c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8 or a fragment thereof; or
(d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or suspectability to a disease, particularly epilepsy, stroke, Alzheimer's disease, pain or migraine amongst others.

The following definitions are provided to facilitate understanding of certain terms used frequently herein.

"Neuroprotection" is the process of rescue/saving of neurones from a substance/condition/event that would otherwise have triggered to the death/degeneration/loss of viability of the neurone.

"Excitotoxicity" is a form of neuronal cell death which is characterised by excessive release (metabolic or otherwise) of glutamate, and subsequent excessive glutamate receptor stimulation. A form of neuronal cell death which is typically prevented by the administration of glutamate receptor antagonists, such as MK-801 or AP5.

"HCN channel" is a selective sodium/potassium permeable cation channel that is activated by membrane hyperpolarisation and modulated by cAMP and cGMP. Activation of HCN channels will typically lead to the development of an inward current carried by sodium/potassium which causes depolarisation of the membrane potential. "An HCN channel" as used herein can refer to one or more of the HCN1, HCN2, HCN3 or HCN4 channels in any combination, either in a homooligomeric or a heterooligomeric arrangement.

"Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucloetide sequence that is shorter than the reference sequence of SEQ ID NO:1 or SEQ ID NO:3.

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, *e.g.*, EP-A 0232 262]. On the other hand, for some uses, it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected, and purified.

"Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared. For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole

length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J., *et al, Nucleic Acids Res*, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (*J. Mol. Biol.,* 147:195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP aligns two sequences, finding a "maximum similarity", according to the algorithm of Neddleman and Wunsch (*J. Mo.l Biol.,* 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, respectively. Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S.F., *et al., J. Mol. Biol.,* 215, 403-410, 1990, Altschul S.F., *et al., Nucleic Acids Res.,* 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at www.ncbi.nlm.nih.gov) and FASTA (Pearson W R, *Methods in Enzymology*, 183: 63-99 (1990); Pearson W R and Lipman D.J., *Proc Nat Acad Sci USA,* 85: 2444-2448 (1988) (available as part of the Wisconsin Sequence Analysis Package).

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S. and Henikoff J.G., *Proc. Nat. Acad Sci. USA*, 89: 10915-10919 (1992)) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid sequences before comparison.

Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a polynucleotide or a polypeptide sequence of the present invention, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.

Alternatively, for instance, for the purposes of interpreting the scope of a claim including mention of a "% identity" to a reference polynucleotide, a polynucleotide sequence having, for example, at least 95% identity to a reference polynucleotide sequence is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100
5 nucleotides of the reference sequence. Such point mutations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These point mutations may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups
10 within the reference sequence. In other words, to obtain a polynucleotide sequence having at least 95% identity to a reference polynucleotide sequence, up to 5% of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as herein before described. The same applies *mutatis mutandis* for other % identities such as 96%, 97%, 98%, 99% and 100%.

15 For the purposes of interpreting the scope of a claim including mention of a "% identity" to a reference polypeptide, a polypeptide sequence having, for example, at least 95% identity to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include up to five point mutations per each 100 amino acids of the reference sequence. Such point mutations are selected from the group consisting of at least one amino acid
20 deletion, substitution, including conservative and non-conservative substitution, or insertion. These point mutations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a sequence polypeptide sequence
25 having at least 95% identity to a reference polypeptide sequence, up to 5% of the amino acids of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other % identities such as 96%, 97%, 98%, 99%, and 100%.

A preferred meaning for "identity" for polynucleotides and polypeptides, as the case may
30 be, are provided in (1) and (2) below.

(1) Polynucleotide embodiments further include an isolated polynucleotide comprising a polynucleotide sequence having at least a 95, 97 or 100% identity to the reference sequence of SEQ ID NO:1, wherein said polynucleotide sequence may be identical to the reference sequence of SEQ ID NO:1 or may include up to a certain integer number of nucleotide alterations as compared to the
35 reference sequence, wherein said alterations are selected from the group consisting of at least one

nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence, and
5 wherein said number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:1 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleotides in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \bullet y),$$

10

wherein n_n is the number of nucleotide alterations, x_n is the total number of nucleotides in SEQ ID NO:1, y is 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and • is the symbol for the multiplication operator, and wherein any non-integer product of x_n and y is rounded down to the nearest integer prior to subtracting it from x_n. Alterations of a polynucleotide sequence encoding the polypeptide
15 of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

(2) Polypeptide embodiments further include an isolated polypeptide comprising a polypeptide having at least a 95, 97 or 100% identity to a polypeptide reference sequence of SEQ ID NO:2, wherein said polypeptide sequence may be identical to the reference sequence of SEQ ID
20 NO:2 or may include up to a certain integer number of amino acid alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either
25 individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of amino acid alterations is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

30

$$n_a \leq x_a - (x_a \bullet y),$$

wherein n_a is the number of amino acid alterations, x_a is the total number of amino acids in SEQ ID NO:2, y is 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and • is the symbol for the multiplication

operator, and wherein any non-integer product of x_a and y is rounded down to the nearest integer prior to subtracting it from x_a.

"Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

"Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

"Polynucleotide" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs comprising one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, *i.e.*, peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may comprise amino acids other

than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications
5 may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may comprise many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and
10 branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation,
15 demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance,
20 PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter, *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth. Enzymol.*
25 (1990) 182:626-646 and Rattan, *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62).

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in
30 the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the
35 sequences of the reference polypeptide and the variant are closely similar overall and, in many

regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is
5 not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

All publications including, but not limited to, patents and patent applications, cited in this specification or to which this patent application claims priority, are herein incorporated by
10 reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

Examples

Example 1 – Human tissue localisation of HCN1 mRNA

TaqMan quantitative RT-PCR was carried out as previously described (Medhurst et al.(1999) Br. J. Pharmacol. 128:627-636. Human polyA+ mRNA samples were obtained from Clontech. OligodT-primed cDNA synthesis was performed in triplicate using 200 ng human polyA+ mRNA and Superscript II reverse transcriptase according to manufacturers instructions (Life Technologies). TaqMan PCR assays were performed on cDNA samples or genomic DNA standards in 96-well optical plates on an ABI Prism 7700 Sequence Detection system (PE Applied Biosystems) according to manufacturers instructions. The primer and probe sequences were as follows:

For human HCN1:

sense	5'- GGCCATGCTGACCAAGCT	SEQ ID NO:9
antisense	5'- GTGCCTTCGCGGATGATG	SEQ ID NO:10
probe	5'- TCACCCGGCTGGAAGACCTCGA	SEQ ID NO:11

For human GAPDH:

sense	5'- TGAGACAGCAGATAGAGCCAAGC	SEQ ID NO:12
antisense	5'- TCCCTGCCAATTTGACATCTTC	SEQ ID NO:13
probe	5'- CATCACCATTGGCAATGAGCGGTTCC	SEQ ID NO:14

Data were analysed using the relative standard curve method with each sample being normalised to GAPDH to correct for differences in RNA quality and quantity (Medhurst et al (1999) supra).

The human HCN1 channel was found to have a distinct tissue distribution, being found in the hypothalamus, the olfactory bulb, neocortex, piriform cortex, hippocampal pyrimidal cell layers CA1-CA3, thalamus and the cerebellum (molecular layer, Purkinje cells, granule cells).

Further localisation studies have showed that HCN1, HCN2, HCN3 and HCN4 mRNAs can all be detected in rat spinal cord and dorsal root ganglia. HCN1 and HCN2 mRNA are expressed in spinal cord at higher levels than HCN3 and HCN4 (approximately 5-fold), whilst in dorsal root ganglia HCN1 is expressed at higher quantities than either HCN2, HCN3 or HCN4 (approximately 10-fold) (figure 1).

Example 2 – Oxygen/Glucose deprivation of Hippocampal Organotypic Slice Cultures

Organotypic hippocampal slice cultures were prepared using the method of Stoppini et al (1991) J.Neurosci Methods 37, 173-182. In brief, hippocampi were isolated from 8-10 day old Lister Hooded rat pups and sliced into 400 µm transverse sections using a McIlwain tissue chopper. Slices were placed into ice cold Geys balanced salt solution (supplemented with 5mg/ml
5 glucose and 1.5% fungizone (GIBCO/BRL). From here slices were transferred onto semiporous membranes (Millipore) at the interface of a support medium comprising 50% minimal essential medium (MEM, ICN), 25% Hanks' balanced salt solution (ICN), 25% heat inactivated horse serum (GIBCO/BRL) supplemented with 5 mg/ml glucose, 1mM glutamine and 1.5% fungizone. Slices were maintained in this configuration in a 5% CO_2 incubator maintained at 37°C for 14
10 days with the support medium being changed every 3 days.

On the day of the insult organotypic slice cultures were intially placed in serum-free medium containing 5 µg/ml of the fluorescent exclusion dye propidium iodide (PI, Molecular Probes) and imaged using a Zeiss Axiovert 135 microscope and Photonic Science CCD Camera. Any cultures which exhibited PI fluorescence were discarded. The remaining slices were then
15 subjected to an anoxic insult either in the absence or presence of ZD7288. The anoxic insult was induced by replacing the normal culture medium with serum free medium which had previously been saturated with 95% N_2/5% CO_2. The cultures were then placed into an airtight incubation chamber equipped with inlet and outlet valves and 95% N_2/5% CO_2 blown through the chamber for 40 min to ensure maximal removal of oxygen. Following hypoxia cultures were transferred to
20 normal serum free medium and placed in a 5% CO_2 incubator at 37°C for 24 hrs before being assessed for neuronal damage using the PI staining protocol described above. Quantification of the extent of damage in the hippocampal CA1 region was assessed using IMAGE 1.55 analysis software (Wayne Rasband, NIH). A summary of the results is provided in Table 1 and figure 2.

Table 1

25

TREATMENT	DAMAGE (% Cell Loss)
INSULT	79.2 ± 4.1
INSULT + ZD-7288 (10 µM)[1]	4.58 ± 3.09
INSULT + ZD-7288 (1 µM)[1]	0.72 ± 0.44
INSULT + ZD-7288 (300 nM)[1]	15.12 ± 9.54
INSULT + ZD-7288 (100 nM)[1]	64.01 ± 4.66
INSULT	55.64 ± 17.72
INSULT + ZD-7288 (100µM)[2]	12.50 ± 8.24
INSULT + MK-801 (10µM)[2]	34.90 ± 15.99



[1] Indicates that compounds were added for 60 minutes before, during, and for 24h after the insult.
[2] Indicates that compounds were added immediately after the insult and for the 24h recovery period only.

5

Figure 3 shows that when ZD7288 was applied immediately after oxygen glucose deprivation neuroprotection was still observed. Figure 3 also shows that in ZD7288 treated slices subjected to OGD it is possible to evoke normal electrophysiological responses in stratum pyramidale and stratum radiatum of area CA1 using single-shock electrical stimulation in stratum radiatum.

10

Example 3 – Excitotoxicity in dispersed primary hippocampal cultures

Primary Hippocampal Cell cultures were prepared as follows. Hippocampi were isolated from embryonic Sprague Dawley rats (gestational age 17.5 days; Charles River), incubated with 0.08% (w/v) trypsin, and dissociated in Neurobasal medium containing 10% heat-inactivated fetal
15 calf serum (Skaper et al.(1990) Methods in Neurosciences, Vol. 2 (Conn P.M., ed), pp. 17-33 Academic Press, San Diego). Cells were pelleted by centrifugation (200g, 5 min) and resuspended in Neurobasal medium containing B27 supplements (with antioxidants), 25 μM glutamate, 1 mM sodium pyruvate, 2 mM L-glutamine, 50 U/ml penicillin, and 50 μg/ml streptomycin. The cell suspension was plated onto poly-D-lysine (10 μg/ml) coated 48-well culture plates (Nunc), at a
20 density of 4.5 x 10^4 cells per cm^2. Cultures were maintained at 37°C in a humidified atmosphere of 5% CO_2-95% air. After 5 days, one-half the medium was replaced with an equal volume of maintenance medium (plating medium but containing B27 supplements without antioxidants, and lacking glutamate). Additional medium exchanges (0.5 volume) were performed every 3-4 days thereafter. Cells were used between 14-16 days in culture. During this period, neurons developed
25 extensive neuritic networks, and formed functional synapses

Neurotoxicity was induced as follows. Cultures were washed once with Locke's solution (pH 7.0-7.4) (Skaper et al. (1990) supra) with or without 1 mM magnesium chloride ($MgCl_2$). To induce sub-maximal neurotoxicity, cultures were exposed for 15 min at room temperature to
30 $MgCl_2$-free Locke's solution, supplemented with 0.1 μM glycine and 30 μM histamine. Thereafter, cells were washed with complete Locke's solution and returned to their original culture medium for 24 h. Cytotoxicity was evident during the 24 h after the insult. Viable neurons had phase-bright somata of round-to-oval shape, with smooth, intact neurites. Neurons were considered nonviable when they exhibited neurite fragmentation and somatic swelling and
35 vacuolation. Cell survival was quantified 24 h after the insult by a colorimetric reaction with 3-

(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Mosmann (1983) J. Immunol. Methods 65:55-63; Manthorpe et al. (1986) Dev. Brain Res. 25:191-198; Skaper et al., (1990) supra). Absolute MTT values obtained were normalized and expressed as a percentage of sham-treated sister cultures (defined as 100%). Control experiments showed that the loss of viable
5 neurons assessed in this manner was proportional to the number of neurons damaged, as estimated by trypan blue staining.
The results, given in Table 2, show that in the hippocampal neurones ZD7288 was neuroprotective (IC_{50} for inhibition of damage of approximately 120 μM). Figure 4 shows that the application of ZD7288 can be delayed for up to 60 minutes after the insult without loss of it's
10 neuroprotective efficacy.

Table 2

TREATMENT	NEURONAL SURVIVAL (%)
CONTROL	100 ± 4
INSULT	46.2 ± 6.9
INSULT + ZD-7288 (300μM)[1]	88.5 ± 2.7
INSULT + ZD-7288 (100μM)[1]	65.9 ± 3.7
INSULT + ZD-7288 (30μM)[1]	56.7 ± 2.0
INSULT + ZD-7288 (10μM)[1]	48.4 ± 5.5
INSULT + ZD-7288 (3μM)[1]	40.1 ± 8.1
INSULT + ZD-7288 (1μM)[1]	40.6 ± 4.9
INSULT + ZD-7288 (300μM)[2]	97.9 ± 9.6
INSULT + ZD-7288 (100μM)[2]	79.5 ± 2.1
INSULT + ZD-7288 (300μM)[3]	101.0 ± 1.2
INSULT + ZD-7288 (100μM)[3]	78.0 ± 5.5
INSULT + MK-801 (10μM)[2]	101 ± 1.2
INSULT + TTX (1μM)[2]	93.4 ± 8.7

15

[1] Indicates that compounds were added for 30 minutes before, during, and for 24h after the insult.
[2] Indicates that compounds were added during the insult only.
[3] Indicates that compounds were added during the 24h recovery period only.

20

Example 4 – Electrophysiological analysis of cell culture models: Detection of I_h

Electrophysiological analysis of neurones from both culture models, using the whole-cell patch-clamp technique, revealed the presence of I_h (figure 5). This current resembled tghat evoked

in Cv1 cells expressing HCN1 (figure 5). Thus the current was activated under voltage-clamp recording conditions by hyperpolarizing steps (1 s in duration) from a holding potential of –50 mV. Succesive hyperpolarizing steps were increased in magnitude, in increments of 10 mV, such that the largest step hyperpolarized the cells to -120 mV. The hyperpolarization-activated current
5 that was recorded exhibited all the the previously published kinetic and voltage dependent characteristics described for I_h and was inhibited by application of either ZD7288 (0.1-100 μM) or extracellular Cs^+ (5 mM). Thus, I_h was almost completely blocked by the application of either 100 μM ZD7288 or 5 mM Cs^+.

Analysis of the synaptic connectivity in hippocampal cultures revealed the presence of a
10 high level of inhibitory GABA and excitatory glutamate receptor-mediated spontaneous activity (figure 6) that was greatly increased when Mg^{2+} was removed from, and glycine/histamine simultaneously added to, the bathing medium (figure 7). When Mg^{2+} containing medium was reinstated 15 mins later there was a sustained increase in spontaneous activity above that recorded prior to the Mg^{2+} free challenge. No change in the magnitude of the I_h current was recorded
15 during or after the Mg^{2+} free challenge. However, ZD7288 (100 μM) induced a membrane potential hyperpolarization/outward current (indicative of antagonism of I_h) and reduced spontaneous activity irrespective of whether it was applied before, during or after the Mg^{2+}-free insult (figures 7 and 8). This reduction in activity differed from that induced by the NMDA receptor antagonist AP5 in that the frequency of activity in the presence of ZD7288 was much
20 lower, yet individual events were much larger, than that observed in AP5.

These actions of ZD7288 (100 μM) were selective in that it had no direct effects on action potential firing (i.e. activation of voltage-gated Na^+ and K^+ channels), voltage-gated Ca^{2+} channel activation, NMDA receptor activation or metabotropic glutamate receptor activation. These findings also support the concept that the neuroprotective action of ZD7288 was mediated
25 through inhibition of I_h.

Example 5 – Epileptiform Bursting Activity in Hippocampal Slices

Hippocampal slices were prepared from 4-6 week old rats that had been sacrificed by cervical dislocation and subsequent decapitation in accordance with UK Home Office guidelines.
30 The brain was removed rapidly and hippocampal slices prepared by cutting 400 μm thick horizontal sections through the whole brain minus the cerebellum using a vibroslicer (Campden Instruments, Loughborough, UK). The hippocampus from these sections was dissected free from the surrounding brain regions and the resultant hippocampal slices placed on a nylon mesh at the interface of a warmed (32-34 °C), perfusing (1-2 $ml.min^{-1}$) artificial cerebrospinal fluid (aCSF)
35 and an oxygen-enriched (95% O_2, 5% CO_2), humidified atmosphere. The standard perfusion

medium comprised (mM): NaCl, 124; KCl, 3; $NaHCO_3$, 26; NaH_2PO_4, 1.25; $CaCl_2$, 2; $MgSO_4$, 1; D-glucose, 10; and was bubbled with 95% O_2, 5% CO_2. Extracellular field potential recordings were made using glass microelectrodes (2-4 MΩ) filled with aCSF placed in stratum pyramidale in area CA3. Spontaneous epileptiform activity was induced by (1) disinhibiting
5 slices using bath application of the $GABA_A$ receptor antagonist bicuculline at 10 μM (figure 9), (2) enhancing NMDA receptor-mediated activity by removing extracellular Mg^{2+} (figure 10) and (3) increasing neuronal excitability using the K^+ channel blocker 4-aminopyridine (4-AP) (figure 11) . Non synaptic field bursting activity (that is relevant to both epilepsy and migraine) was induced by removal of extracellular Ca^{2+} and elevation of extracellular K^+ from 3 mM to 6-8 mM
10 (figure 12). ZD7288 was deemed to have an effect on these models of neuronal hyperexcitability if it altered the frequency of events by more than 10%. Irrespective of which model was studied ZD7288 produced a concentration dependent inhibition of epileptiform bursting activity

Example 6 Suprachiasmatic Nucleus Function

15 Supraachiasmatic nucleus slices were prepared from 4-6 week old rats that had been sacrificed by cervical dislocation and subsequent decapitation in accordance with UK Home Office guidelines. The brain was removed rapidly and SCN slices prepared by cutting 400 μm thick coronal sections through the whole brain minus the cerebellum using a vibroslicer (Campden Instruments, Loughborough, UK). The resultant SCN slices were placed in a warmed
20 (32-34 ^oC) submersion recording chamber perfused at 1-2 $ml.min^{-1}$ with an oxygen-enriched (95% O_2, 5% CO_2) artificial cerebrospinal fluid (aCSF) comprised of (mM): NaCl, 124; KCl, 3; $NaHCO_3$, 26; NaH_2PO_4, 1.25; $CaCl_2$, 2; $MgSO_4$, 1; D-glucose, 10. Extracellular single unit recordings were made using glass microelectrodes (2-4 MΩ) filled with aCSF placed in the SCN. In all neurones tested ZD7288 (10-100 μM) caused a concentration dependent reduction in the
25 frequency of single unit firing (figure 13).

Example 7 – Representational Difference Analysis

The representational difference analysis (RDA) subtractive hybridisation protocol was
30 performed on ipsilateral cortex derived from MCAO (middle cerebral artery occlusion) rats (Aspey, B.S. et al (1998) Neuropathology and Applied Neurobiology 24 p487-497) essentially as described previously (Hubank and Shatz, Nucleic Acid Research (1994), 22, 5640-5648). Briefly, 5μg of poly A^+ mRNA from both "tester" (normotensive rats 24hrs following permanent MCAO) and "driver" (sham operated rats) was used to generate dscDNA. Poly A^+ mRNA served
35 as a template for oligodT primed reverse transcription followed by RNAse H primed second

strand synthesis. Representations for both tester and driver were generated by restriction of the dscDNA with Dpn II, and ligation to oligos (R-Bgl-24 and R-Bgl-12). PCR amplification with R-Bgl-24 served to generate rationalised cDNA libraries, or representations, for both tester and driver samples. The R-Bgl-24 oligo was removed from the representations by digestion with DpnII, at which point the driver representation was completed, while the tester representation was ligated to a fresh oligo pair (J-Bgl-24 and J-Bgl-12). Subtractive hybridisation was performed for 20hrs at 67°C in 4μl of EEx3 buffer at a tester to driver ratio of 1:100. Following subtraction, the hybridised cDNA was diluted in TE and cDNAs expressed at higher levels in the tester rather than driver were identified by amplification with J-Bgl-24 to generate the first difference product (DP-1). The J-Bgl-24 oligo was removed by DpnII restriction and replaced with a fresh oligo pair (N-Bgl-24 and N-Bgl-12). The N-Bgl-24 ligated cDNA served as a template for a second round of subtractive hybridisation, this time using a tester:driver ratio of 1:800. Again, differentially expressed clones were preferentially amplified from the subtracted cDNA using the tester specific oligo N-Bgl-24, to generate the second difference product (DP-2).

The subtracted library (DP-2) was restricted with DpnII and ligated into the BamH1 site of the plasmid vector pcDNA3.1, before transformation into competent bacteria. Bacterial colonies were PCR screened for inserts using vector primers, and plasmid DNA extracted from positive colconies. Clones were subjected to automated sequence analysis with vector primers and identities confirmed by Blast analysis of the Genbank/EMBL databases.

Oligonucleotides (5' to 3'):

R-Bgl-24	AGCACTCTCCAGCCTCTCACCGCA	SEQ ID NO:15
R-Bgl-12	GATCTGCGGTGA	SEQ ID NO:16
J-Bgl-24	ACCGACGTCGACTATCCATGAACA	SEQ ID NO:17
J-Bgl-12	GATCTGTTCATG	SEQ ID NO:18
N-Bgl-24	AGGCAACTGTGCTATCCGAGGGAA	SEQ ID NO:19
N-Bgl-12	GATCTTCCCTCG	SEQ ID NO:20

Results

4 clones were identified, which rationalised into 2 contigs, that showed strong homolgy to the mouse hyperpolarising ion channel HCN4/HAC4/BCNG-3 (Accession number AF064874) in both BLASTN and BLASTX searches. Contig 545 shows 94% identity over nucleotides 65 to 301 to murine HCN4, while contig 575 shows 93% identity over nucleotides 964 to 1203 to murine HCN4 . BLASTX searches showed a 93% and 100% identity for contigs 545 and 575, respectively, to murine HCN4 over the same regions.

Example 8 - Suppressive Subtractive Hybridisation (SSH)

SSH was performed essentially as described by the manufacturers (PCR-select Clontech, Diatchenko et al. PNAS 93:6025-6030, 1996). Normotensive rats 24hrs post permanent MCAO served as the tester, while sham-treated animals at the same timepoint were used as the driver. 2ug of polyA$^+$ mRNA was used to generate dscDNA, which was restricted with RsaI, at which point the driver was complete, while the tester was further ligated independently to two-sets of adaptors (1 and 2R). The two sets of adaptor-ligated tester cDNAs were independently hybridised with driver at a ratio of tester:driver of 1:30 for 8hrs at 68°C, at which point the samples were combined, the tester:driver ratio increased to 1:36 and hybridisation continued for 18hrs. Gene products expressed at higher levels in the tester than the driver were more likely to form cDNA with different oligos at either end, and are therefore immune from the suppression of PCR amplification. Differentially expressed transcripts were amplified by two round of PCR and cloned into pCDNA3.1/V5-His-TOPO (InVitrogen) using the topoisomerase-I ligation method. Clones were subjected to automated sequence analysis with vector primers and identities confirmed by Blast analysis of the Genbank/EMBL databases.

Adaptor oligonucleotides (5' to 3'):

1	CTAATACGACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGT ACCTGCCCGG	SEQ ID NO:21
2R	CTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAGGT ACCTCGGCCG	SEQ ID NO:22

PCR primer 1	CTAATACGACTCACTATAGGGC	SEQ ID NO:23
nested primer 1	TCGAGCGGCCGCCCGGGCAGGT	SEQ ID NO:24
primer 2R	CTAATACGACTCACTATAGGGC	SEQ ID NO:25
nested primer 2R	AGCGTGGTCGCGGCCGAGGT	SEQ ID NO:26

Results:

Blast analysis of the subtracted library showed that one clone, clone 39, showed high homology to the murine HCN1/HAC2/BCNG-1gene (Accession number: AJ225123). Clone 39 shows 93% identity to mHCN1 at the nucleotide level, and 98% identity at the amino acid level over the region 2152-2418bp of AJ225123.

SEQUENCE INFORMATION

SEQ ID NO:1

ATGGAAGGAGGCGGCAAGCCCAACTCTTCGTCTAACAGCCGGGACGATGGCAACAGCGTC
TTCCCCGCCAAGGCGTCCGCGCCGGGCGCGGGGCCGGCCGCGGCCGAGAAGCGCCTGGGC
ACCCCGCCGGGGGGCGGCGGGGCCGGCGCGAAGGAGCACGGCAACTCCGTGTGCTTCAAG
GTGGACGGCGGTGGCGGCGGTGGCGGCGGCGGCGGCGGCGGCGAGGAGCCGGCGGGGGGC
TTCGAAGACGCCGAGGGGCCCCGGCGGCAGTACGGCTTCATGCAGAGGCAGTTCACCTCC
ATGCTGCAGCCCGGGGTCAACAAATTCTCCCTCCGCATGTTTGGGAGCCAGAAGGCGGTG
GAAAAGGAGCAGGAAAGGGTTAAAACTGCAGGCTTCTGGATTATCCACCCTTACAGTGAT
TTCAGGTTTTACTGGGATTTAATAATGCTCATAATGATGGTTGGAAATCTAGTCATCATA
CCAGTTGGAATCACATTCTTTACAGAGCAAACAACAACACCATGGATTATTTTCAATGTG
GCATCAGATACAGTTTTCCTATTGGACCTGATCATGAATTTTAGGACTGGGACTGTCAAT
GAAGACAGTTCTGAAATCATCCTGGACCCCAAAGTGATCAAGATGAATTATTTAAAAAGC
TGGTTTGTGGTTGACTTCATCTCATCCATCCCAGTGGATTATATCTTTCTTATTGTAGAA
AAAGGAATGGATTCTGAAGTTTACAAGACAGCCAGGGCCCTTCGCATTGTGAGGTTTACA
AAAATTCTCAGTCTCTTGCGTTTATTACGACTTTCAAGGTTAATTAGATACATACATCAA
TGGGAAGAGATATTCCACATGACATATGATCTCGCCAGTGCAGTGGTGAGAATTTTTAAT
CTCATCGGCATGATGCTGCTCCTGTGCCACTGGGATGGTTGTCTTCAGTTCTTAGTACCA
CTACTGCAGGACTTCCCACCAGATTGCTGGGTGTCTTTAAATGAAATGGTTAATGATTCT
TGGGGAAAGCAGTATTCATACGCACTCTTCAAAGCTATGAGTCACATGCTGTGCATTGGG
TATGGAGCCCAAGCCCCAGTCAGCATGTCTGACCTCTGGATTACCATGCTGAGCATGATC
GTCGGGGCCACCTGCTATGCCATGTTTGTCGGCCATGCCACCGCTTTAATCCAGTCTCTG
GATTCTTCGAGGCGGCAGTATCAAGAGAAGTATAAGCAAGTGGAACAATACATGTCATTC
CATAAGTTACCAGCTGATATGCGTCAGAAGATACATGATTACTATGAACACAGATACCAA
GGCAAAATCTTTGATGAGGAAAATATTCTCAATGAACTCAATGATCCTCTGAGAGAGGAG
ATAGTCAACTTCAACTGTCGGAAACTGGTGGCTACAATGCCTTTATTTGCTAATGCGGAT
CCTAATTTTGTGACTGCCATGCTGAGCAAGTTGAGATTTGAGGTGTTTCAACCTGGAGAT
TATATCATACGAGAAGGAGCCGTGGGTAAAAAAATGTATTTCATTCAACACGGTGTTGCT
GGTGTCATTACAAAATCCAGTAAAGAAATGAAGCTGACAGATGGCTCTTACTTTGGAGAG
ATTTGCCTGCTGACCAAAGGACGTCGTACTGCCAGTGTTCGAGCTGATACATATTGTCGT
CTTTACTCACTTTCCGTGGACAATTTCAACGAGGTCCTGGAGGAATATCCAATGATGAGG
AGAGCCTTTGAGACAGTTGCCATTGACCGACTAGATCGAATAGGAAAGAAAAATTCAATT
CTTCTGCAAAAGTTCCAGAAGGATCTGAACACTGGTGTTTTCAACAATCAGGAGAACGAA
ATCCTCAAGCAGATTGTGAAACATGACAGGGAGATGGTGCAGGCAATCGCTCCCATCAAT
TATCCTCAAATGACAACCCTGAATTCCACATCGTCTACTACGACCCCGACCTCCCGCATG
AGGACACAATCTCCACCGGTGTACACAGCGACCAGCCTGTCTCACAGCAACCTGCACTCC
CCCAGTCCCAGCACACAGACCCCCCAGCCATCAGCCATCCTGTCACCCTGCTCCTACACC
ACCGCGGTCTGCAGCCCTCCTGTACAGAGCCCTCTGGCCGCTCGAACTTTCCACTATGCC
TCCCCCACCGCCTCCCAGCTGTCACTCATGCAACAGCAGCCGCAGCAGCAGGTACAGCAG
TCCCAGCCGCCGCAGACTCAGCCACAGCAGCCGTCCCCGCAGCCACAGACACCTGGCAGC
TCCACGCCGAAAAATGAAGTGCACAAGAGCACGCAGGCGCTTCACAACACCAACCTGACC

CGGGAAGTCAGGCCATTTTCCGCCTGGCAGCCNTCGCTGCCCCATGAGGTGTCCACTTTG
ATTTCCAGACCTCATCCCACTGTGGGGGAGTCCCTGGCCTCCATCCCTCAACCCGTGACG
GCGGTCCCCGGAACGGGCCTTCAGGCAGGGGGCAGGAGCACTGTCCCGCAGCGCGTCACC
TTTTTCCGACAGATGTCGTCGGGAGCCATCCCCCCGAACCGAGGAGTCCTTCCAGCACCC
CTTCCACCAGCAGCTGCTCTTCCAAGAGAATCTTCCTCAGTCTTAAACACAGACCCAGAC
GCAGAAAAGCCACGATTTGCTTCAAATTTA

SEQ ID NO:2

MEGGGKPNSSSNSRDDGNSVFPAKASAPGAGPAAAEKRLGTPPGGGGAGAKEHGNSVCFK
VDGGGGGGGGGGGGEEPAGGFEDAEGPRRQYGFMQRQFTSMLQPGVNKFSLRMFGSQKAV
EKEQERVKTAGFWIIHPYSDFRFYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIFNV
ASDTVFLLDLIMNFRTGTVNEDSSEIILDPKVIKMNYLKSWFVVDFISSIPVDYIFLIVE
KGMDSEVYKTARALRIVRFTKILSLLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFN
LIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLCIG
YGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLDSSRRQYQEKYKQVEQYMSF
HKLPADMRQKIHDYYEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMPLFANAD
PNFVTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTDGSYFGE
ICLLTKGRRTASVRADTYCRLYSLSVDNFNEVLEEYPMMRRAFETVAIDRLDRIGKKNSI
LLQKFQKDLNTGVFNNQENEILKQIVKHDREMVQAIAPINYPQMTTLNSTSSTTTPTSRM
RTQSPPVYTATSLSHSNLHSPSPSTQTPQPSAILSPCSYTTAVCSPPVQSPLAARTFHYA
SPTASQLSLMQQQPQQQVQQSQPPQTQPQQPSPQPQTPGSSTPKNEVHKSTQALHNTNLT
REVRPFSAWQPSLPHEVSTLISRPHPTVGESLASIPQPVTAVPGTGLQAGGRSTVPQRVT
FFRQMSSGAIPPNRGVLPAPLPPAAALPRESSSVLNTDPDAEKPRFASNL

Claims

1. The use of a compound selected from:

(a) an HCN channel polypeptide, or a fragment thereof;

(b) a compound which inhibits an HCN channel polypeptide;

(c) a compound which activates an HCN channel polypeptide; or

(d) a polynucleotide capable of inhibiting the expression of an HCN channel polypeptide,

for the manufacture of a medicament for treating, stroke, ischaemia, head injury, epilepsy, Alzheimer's disease, Parkinson's disease, learning or memory and attention disorders.

2. The use according to claim 1 wherein the medicament comprises an isolated polypeptide which comprises a polypeptide having at least 99% identity to the HCN channel polypeptide of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8.

3. The use according to claim 2 wherein the isolated polypeptide is the HCN channel polypeptide of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8.

4. The use according to claim 1 wherein the medicament comprises a compound which inhibits an HCN channel polypeptide.

5. The use according to claim 1 wherein the medicament comprises a compound which activates an HCN channel polypeptide.

6. The use according to claim 1 wherein the polynucleotide comprises a polynucleotide having at least 95% identity with the polynucleotide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.

7. The use according to claim 6 wherein the polynucleotide has the polynucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7.

8. The use of a compound selected from:

(a) an HCN channel polypeptide, or a fragment thereof;

(b) a compound which inhibits an HCN channel polypeptide;

(c) a compound which activates an HCN channel polypeptide; or

(d) a polynucleotide capable of inhibiting the expression of an HCN channel polypeptide,

for the manufacture of a medicament for treating pain, gut disorders, in particular IBS, or sleep disorders.

9. The use according to claim 8 wherein the medicament comprises an isolated polypeptide which comprises a polypeptide having at least 99% identity to the HCN channel polypeptide of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8.

10. The use according to claim 9 wherein the isolated polypeptide is the HCN channel polypeptide of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8.

11. The use according to claim 8 wherein the medicament comprises a compound which inhibits an HCN channel polypeptide.

12. The use according to claim 8 wherein the medicament comprises a compound which activates an HCN channel polypeptide.

13. The use according to claim 8 wherein the polynucleotide comprises a polynucleotide having at least 95% identity with the polynucleotide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.

14. The use according to claim 13 wherein the polynucleotide has the polynucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7.

15. An isolated polypeptide selected from the group consisting of:

(a) an isolated polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO:1;

(b) an isolated polypeptide comprising a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

(c) an isolated polypeptide having at least 95% identity to the polypeptide sequence of SEQ ID NO:2; and

(d) fragments and variants of such polypeptides in (a) to (c).

16. The isolated polypeptide as claimed in claim 15 comprising the polypeptide sequence of SEQ ID NO:2.

17. The isolated polypeptide as claimed in claim 15 which is the polypeptide sequence of SEQ ID NO:2.

18. An isolated polynucleotide selected from the group consisting of:
(a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO:1;
(b) an isolated polynucleotide having at least 95% identity to the polynucleotide of SEQ ID NO:1;
(c) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;
(d) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;
(e) an isolated polynucleotide with a nucleotide sequence of at least 100 nucleotides obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof having at least 15 nucleotides;
(f) a polynucleotide which is the RNA equivalent of a polynucleotide of (a) to (e);
or a polynucleotide sequence complementary to said isolated polynucleotide
and polynucleotides that are variants and fragments of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

19. An isolated polynucleotide as claimed in claim 18 selected from the group consisting of:
(a) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1;
(b) the isolated polynucleotide of SEQ ID NO:1;
(c) an isolated polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2; and
(d) an isolated polynucleotide encoding the polypeptide of SEQ ID NO:2.

20. An expression vector comprising a polynucleotide capable of producing a polypeptide of claim 15 when said expression vector is present in a compatible host cell.

21. A recombinant host cell comprising the expression vector of claim 20 or a membrane thereof expressing the polypeptide of claim 1.



Figure 1



Figure 2



Figure 3

Effects of Post-Treatment of ZD-7288 on Mg-Deprivation Induced Neurodegeneration.



Figure 4

Activation of HCN Channels in Hippocampal Neurones and HCN1 in CV1 Cells Generates a Current called I_h that is blocked by ZD-7288 and Cs^+



Figure 5



Figure 6

ZD-7288 Inhibits the Increase in Spontaneous activity induced by a Mg^{2+} Free Insult



Figure 7



Figure 8



Figure 9

ZD7288 Inhibits 0 Mg^{2+} Induced Epileptiform Bursting In Adult Hippocampal Slices



Figure 10

ZD7288 Inhibits 4-AP induced Epileptiform Bursting



Figure 11

ZD7288 Inhibits Non Synaptic Field Bursting

6 mM K^+ + 0 mM Ca^{2+}



Figure 12

ZD-7288 Reduces the Frequency of
Single Unit Firing
in the Suprachiasmatic Nucleus



Figure 13

SEQUENCE LISTING

<110> SmithKline Beecham plc

<120> New Use

<130> P32614

<160> 26

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 2670
<212> DNA
<213> Homo sapiens

<400> 1
```
atggaaggag gcggcaagcc caactcttcg tctaacagcc gggacgatgg caacagcgtc      60
ttccccgcca aggcgtccgc gccgggcgcg gggccggccg cggccgagaa gcgcctgggc     120
accccgccgg ggggcggcgg ggccggcgcg aaggagcacg gcaactccgt gtgcttcaag     180
gtggacggcg gtggcggcgg tggcggcggc ggcggcggcg gcgaggagcc ggcggggggc     240
ttcgaagacg ccgaggggcc ccggcggcag tacggcttca tgcagaggca gttcacctcc     300
atgctgcagc ccggggtcaa caaattctcc ctccgcatgt ttgggagcca gaaggcggtg     360
gaaaaggagc aggaaagggt taaaactgca ggcttctgga ttatccaccc ttacagtgat     420
ttcaggtttt actgggattt aataatgctc ataatgatgg ttggaaatct agtcatcata     480
ccagttggaa tcacattctt tacagagcaa acaacaacac catggattat tttcaatgtg     540
gcatcagata cagttttcct attggacctg atcatgaatt ttaggactgg gactgtcaat     600
gaagacagtt ctgaaatcat cctggacccc aaagtgatca agatgaatta tttaaaaagc     660
tggtttgtgg ttgacttcat ctcatccatc ccagtggatt atatcttttct tattgtagaa     720
aaaggaatgg attctgaagt ttacaagaca gccagggccc ttcgcattgt gaggtttaca     780
aaaattctca gtctcttgcg tttattacga ctttcaaggt taattagata catacatcaa     840
tgggaagaga tattccacat gacatatgat ctcgccagtg cagtggtgag aatttttaat     900
ctcatcggca tgatgctgct cctgtgccac tgggatggtt gtcttcagtt cttagtacca     960
ctactgcagg acttcccacc agattgctgg gtgtctttaa atgaaatggt taatgattct    1020
tggggaaagc agtattcata cgcactcttc aaagctatga gtcacatgct gtgcattggg    1080
tatggagccc aagccccagt cagcatgtct gacctctgga ttaccatgct gagcatgatc    1140
gtcggggcca cctgctatgc catgtttgtc ggccatgcca ccgctttaat ccagtctctg    1200
gattcttcga ggcggcagta tcaagagaag tataagcaag tggaacaata catgtcattc    1260
cataagttac cagctgatat gcgtcagaag atacatgatt actatgaaca cagataccaa    1320
ggcaaaatct ttgatgagga aaatattctc aatgaactca atgatcctct gagagaggag    1380
atagtcaact tcaactgtcg gaaactggtg gctacaatgc ctttatttgc taatgcggat    1440
cctaattttg tgactgccat gctgagcaag ttgagatttg aggtgtttca acctggagat    1500
tatatcatac gagaaggagc cgtgggtaaa aaaatgtatt tcattcaaca cggtgttgct    1560
ggtgtcatta caaaatccag taaagaaatg aagctgacag atggctctta ctttggagag    1620
```

```
atttgcctgc tgaccaaagg acgtcgtact gccagtgttc gagctgatac atattgtcgt    1680
ctttactcac tttccgtgga caatttcaac gaggtcctgg aggaatatcc aatgatgagg    1740
agagcctttg agacagttgc cattgaccga ctagatcgaa taggaaagaa aaattcaatt    1800
cttctgcaaa agttccagaa ggatctgaac actggtgttt tcaacaatca ggagaacgaa    1860
atcctcaagc agattgtgaa acatgacagg gagatggtgc aggcaatcgc tcccatcaat    1920
tatcctcaaa tgacaaccct gaattccaca tcgtctacta cgaccccgac ctcccgcatg    1980
aggacacaat ctccaccggt gtacacagcg accagcctgt ctcacagcaa cctgcactcc    2040
cccagtccca gcacacagac cccccagcca tcagccatcc tgtcaccctg ctcctacacc    2100
accgcggtct gcagccctcc tgtacagagc cctctggccg ctcgaacttt ccactatgcc    2160
tcccccaccg cctcccagct gtcactcatg caacagcagc cgcagcagca ggtacagcag    2220
tcccagccgc cgcagactca gccacagcag ccgtccccgc agccacagac acctggcagc    2280
tccacgccga aaaatgaagt gcacaagagc acgcaggcgc ttcacaacac caacctgacc    2340
cgggaagtca ggccattttc cgcctggcag ccntcgctgc cccatgaggt gtccactttg    2400
atttccagac ctcatcccac tgtgggggag tccctggcct ccatccctca acccgtgacg    2460
gcggtccccg gaacgggcct tcaggcaggg ggcaggagca ctgtcccgca gcgcgtcacc    2520
tttttccgac agatgtcgtc gggagccatc cccccgaacc gaggagtcct tccagcaccc    2580
cttccaccag cagctgctct tccaagagaa tcttcctcag tcttaaacac agacccagac    2640
gcagaaaagc cacgatttgc ttcaaattta                                     2670
```

```
<210> 2
<211> 890
<212> PRT
<213> Homo sapiens

<400> 2
Met Glu Gly Gly Gly Lys Pro Asn Ser Ser Ser Asn Ser Arg Asp Asp
1               5                   10                  15
Gly Asn Ser Val Phe Pro Ala Lys Ala Ser Ala Pro Gly Ala Gly Pro
            20                  25                  30
Ala Ala Ala Glu Lys Arg Leu Gly Thr Pro Pro Gly Gly Gly Gly Ala
        35                  40                  45
Gly Ala Lys Glu His Gly Asn Ser Val Cys Phe Lys Val Asp Gly Gly
    50                  55                  60
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Glu Glu Pro Ala Gly Gly
65                  70                  75                  80
Phe Glu Asp Ala Glu Gly Pro Arg Arg Gln Tyr Gly Phe Met Gln Arg
                85                  90                  95
Gln Phe Thr Ser Met Leu Gln Pro Gly Val Asn Lys Phe Ser Leu Arg
            100                 105                 110
Met Phe Gly Ser Gln Lys Ala Val Glu Lys Glu Gln Glu Arg Val Lys
        115                 120                 125
Thr Ala Gly Phe Trp Ile Ile His Pro Tyr Ser Asp Phe Arg Phe Tyr
    130                 135                 140
Trp Asp Leu Ile Met Leu Ile Met Met Val Gly Asn Leu Val Ile Ile
145                 150                 155                 160
Pro Val Gly Ile Thr Phe Phe Thr Glu Gln Thr Thr Thr Pro Trp Ile
                165                 170                 175
```

```
Ile Phe Asn Val Ala Ser Asp Thr Val Phe Leu Leu Asp Leu Ile Met
            180                 185                 190
Asn Phe Arg Thr Gly Thr Val Asn Glu Asp Ser Ser Glu Ile Ile Leu
        195                 200                 205
Asp Pro Lys Val Ile Lys Met Asn Tyr Leu Lys Ser Trp Phe Val Val
    210                 215                 220
Asp Phe Ile Ser Ser Ile Pro Val Asp Tyr Ile Phe Leu Ile Val Glu
225                 230                 235                 240
Lys Gly Met Asp Ser Glu Val Tyr Lys Thr Ala Arg Ala Leu Arg Ile
                245                 250                 255
Val Arg Phe Thr Lys Ile Leu Ser Leu Leu Arg Leu Leu Arg Leu Ser
            260                 265                 270
Arg Leu Ile Arg Tyr Ile His Gln Trp Glu Glu Ile Phe His Met Thr
        275                 280                 285
Tyr Asp Leu Ala Ser Ala Val Val Arg Ile Phe Asn Leu Ile Gly Met
    290                 295                 300
Met Leu Leu Leu Cys His Trp Asp Gly Cys Leu Gln Phe Leu Val Pro
305                 310                 315                 320
Leu Leu Gln Asp Phe Pro Pro Asp Cys Trp Val Ser Leu Asn Glu Met
                325                 330                 335
Val Asn Asp Ser Trp Gly Lys Gln Tyr Ser Tyr Ala Leu Phe Lys Ala
            340                 345                 350
Met Ser His Met Leu Cys Ile Gly Tyr Gly Ala Gln Ala Pro Val Ser
        355                 360                 365
Met Ser Asp Leu Trp Ile Thr Met Leu Ser Met Ile Val Gly Ala Thr
    370                 375                 380
Cys Tyr Ala Met Phe Val Gly His Ala Thr Ala Leu Ile Gln Ser Leu
385                 390                 395                 400
Asp Ser Ser Arg Arg Gln Tyr Gln Glu Lys Tyr Lys Gln Val Glu Gln
                405                 410                 415
Tyr Met Ser Phe His Lys Leu Pro Ala Asp Met Arg Gln Lys Ile His
            420                 425                 430
Asp Tyr Tyr Glu His Arg Tyr Gln Gly Lys Ile Phe Asp Glu Glu Asn
        435                 440                 445
Ile Leu Asn Glu Leu Asn Asp Pro Leu Arg Glu Glu Ile Val Asn Phe
    450                 455                 460
Asn Cys Arg Lys Leu Val Ala Thr Met Pro Leu Phe Ala Asn Ala Asp
465                 470                 475                 480
Pro Asn Phe Val Thr Ala Met Leu Ser Lys Leu Arg Phe Glu Val Phe
                485                 490                 495
Gln Pro Gly Asp Tyr Ile Ile Arg Glu Gly Ala Val Gly Lys Lys Met
            500                 505                 510
Tyr Phe Ile Gln His Gly Val Ala Gly Val Ile Thr Lys Ser Ser Lys
        515                 520                 525
Glu Met Lys Leu Thr Asp Gly Ser Tyr Phe Gly Glu Ile Cys Leu Leu
    530                 535                 540
Thr Lys Gly Arg Arg Thr Ala Ser Val Arg Ala Asp Thr Tyr Cys Arg
```

```
545                 550                 555                 560
Leu Tyr Ser Leu Ser Val Asp Asn Phe Asn Glu Val Leu Glu Glu Tyr
                565                 570                 575
Pro Met Met Arg Arg Ala Phe Glu Thr Val Ala Ile Asp Arg Leu Asp
            580                 585                 590
Arg Ile Gly Lys Lys Asn Ser Ile Leu Leu Gln Lys Phe Gln Lys Asp
        595                 600                 605
Leu Asn Thr Gly Val Phe Asn Asn Gln Glu Asn Glu Ile Leu Lys Gln
    610                 615                 620
Ile Val Lys His Asp Arg Glu Met Val Gln Ala Ile Ala Pro Ile Asn
625                 630                 635                 640
Tyr Pro Gln Met Thr Thr Leu Asn Ser Thr Ser Ser Thr Thr Thr Pro
                645                 650                 655
Thr Ser Arg Met Arg Thr Gln Ser Pro Pro Val Tyr Thr Ala Thr Ser
            660                 665                 670
Leu Ser His Ser Asn Leu His Ser Pro Ser Pro Ser Thr Gln Thr Pro
        675                 680                 685
Gln Pro Ser Ala Ile Leu Ser Pro Cys Ser Tyr Thr Thr Ala Val Cys
    690                 695                 700
Ser Pro Pro Val Gln Ser Pro Leu Ala Ala Arg Thr Phe His Tyr Ala
705                 710                 715                 720
Ser Pro Thr Ala Ser Gln Leu Ser Leu Met Gln Gln Gln Pro Gln Gln
                725                 730                 735
Gln Val Gln Gln Ser Gln Pro Pro Gln Thr Gln Pro Gln Gln Pro Ser
            740                 745                 750
Pro Gln Pro Gln Thr Pro Gly Ser Ser Thr Pro Lys Asn Glu Val His
        755                 760                 765
Lys Ser Thr Gln Ala Leu His Asn Thr Asn Leu Thr Arg Glu Val Arg
    770                 775                 780
Pro Phe Ser Ala Trp Gln Pro Ser Leu Pro His Glu Val Ser Thr Leu
785                 790                 795                 800
Ile Ser Arg Pro His Pro Thr Val Gly Glu Ser Leu Ala Ser Ile Pro
                805                 810                 815
Gln Pro Val Thr Ala Val Pro Gly Thr Gly Leu Gln Ala Gly Gly Arg
            820                 825                 830
Ser Thr Val Pro Gln Arg Val Thr Phe Phe Arg Gln Met Ser Ser Gly
        835                 840                 845
Ala Ile Pro Pro Asn Arg Gly Val Leu Pro Ala Pro Leu Pro Pro Ala
    850                 855                 860
Ala Ala Leu Pro Arg Glu Ser Ser Ser Val Leu Asn Thr Asp Pro Asp
865                 870                 875                 880
Ala Glu Lys Pro Arg Phe Ala Ser Asn Leu
                885                 890
```

<210> 3

<211> 3459

<212> DNA

<213> Homo sapiens

<400> 3

```
ggccggcggc ggcggcggcg gctccgctcc gcactgcccg gcgccgcctc gccatggacg     60
cgcgcggggg cggcgggcgg cccggggaga gcccgggcgc gacccccgcg ccggggccgc    120
cgccgccgcc gccgcccgcg ccccccaac agcagccgcc gccgccgccg ccgcccgcgc    180
ccccccggg ccccgggccc gcgcccccc agcacccgcc ccgggccgag gcgttgcccc    240
cggaggcggc ggatgagggc ggcccgcggg gccggctccg cagccgcgac agctcgtgcg    300
gccgccccgg caccccgggc gcggcgagca cggccaaggg cagcccgaac ggcgagtgcg    360
ggcgcggcga gccgcagtgc agccccgcgg ggcccgaggg cccggcgcgg gggcccaagg    420
tgtcgttctc gtgccgcggg gcggcctcgg ggcccgcgcc ggggccgggg ccggcggagg    480
aggcgggcag cgaggaggcg ggcccggcgg gggagccgcg cggcagccag gccagcttca    540
tgcagcgcca gttcggcgcg ctcctgcagc cgggcgtcaa caagttctcg ctgcggatgt    600
tcggcagcca gaaggccgtg gagcgcgagc aggagcgcgt caagtcggcg gggggcctgga    660
tcatccaccc gtacagcgac ttcaggttct actgggactt caccatgctg ctgttcatgg    720
tgggaaacct catcatcatc ccagtgggca tcaccttctt caaggatgag accactgccc    780
cgtggatcgt gttcaacgtg gtctcggaca ccttcttcct catggacctg gtgttgaact    840
tccgcaccgg cattgtgatc gaggacaaca cggagatcat cctggacccc gagaagatca    900
agaagaagta tctgcgcacg tggttcgtgg tggacttcgt gtcctccatc cccgtggact    960
acatcttcct tattgtggag aagggcattg actccgaggt ctacaagacg gcacgcgccc   1020
tgcgcatcgt gcgcttcacc aagatcctca gcctcctgcg gctgctgcgc ctctcacgcc   1080
tgatccgcta catccatcag tgggaggaga tcttccacat gacctatgac ctggccagcg   1140
cggtgatgag gatctgcaat ctcatcagca tgatgctgct gctctgccac tgggacggct   1200
gcctgcagtt cctggtgcct atgctgcagg acttcccgcg caactgctgg gtgtccatca   1260
atggcatggt gaaccactcg tggagtgaac tgtactcctt cgcactcttc aaggccatga   1320
gccacatgct gtgcatcggg tacggccggc aggcgcccga gagcatgacg gacatctggc   1380
tgaccatgct cagcatgatt gtgggtgcca cctgctacgc catgttcatc ggccacgcca   1440
ctgccctcat ccagtcgctg gactcctcgc ggcgccagta ccaggagaag tacaagcagg   1500
tggagcagta catgtccttc cacaagctgc cagctgactt ccgccagaag atccacgact   1560
actatgagca ccgttaccag ggcaagatgt ttgacgagga cagcatcctg ggcgagctca   1620
acgggcccct gcgggaggag atcgtcaact tcaactgccg gaagctggtg gcctccatgc   1680
cgctgttcgc caacgccgac cccaacttcg tcacggccat gctgaccaag ctcaagttcg   1740
aggtcttcca gccgggtgac tacatcatcc gcgaaggcac catcgggaag aagatgtact   1800
tcatccagca cggcgtggtc agcgtgctca ctaagggcaa caaggagatg aagctgtccg   1860
atggctccta cttcggggag atctgcctgc tcacccgggg ccgccgcacg gcgagcgtgc   1920
gggccgacac ctactgccgc ctctattcgc tgagcgtgga caacttcaac gaggtgctgg   1980
aggagtaccc catgatgcgg cgcgccttcg agacggtggc catcgaccgc ctggaccgca   2040
tcggcaagaa gaattccatc ctcctgcaca aggtgcagca tgacctcaac tcgggcgtat   2100
tcaacaacca ggagaacgcc atcatccagg agatcgtcaa gtacgaccgc gagatggtgc   2160
agcaggccga gctgggtcag cgcgtgggcc tcttcccgcc gccgccgccg ccgccgcagg   2220
tcacctcggc catcgccacg ctgcagcagg cggcggccat gagcttctgc ccgcaggtgg   2280
cgcggccgct cgtggggccg ctggcgctcg gctcgccgcg cctcgtgcgc cgcccgcccc   2340
cggggcccgc acctgccgcc gcctcacccg ggcccccgcc ccccgccagc cccccgggcg   2400
cgcccgccag cccccgggca ccgcggacct cgccctacgg cggcctgccc gccgcccccc   2460
ttgctgggcc cgccctgccc gcgcgccgcc tgagccgcgc gtcgcgccca ctgtccgcct   2520
cgcagccctc gctgcctcac ggcgcccccg gccccgcggc ctccacacgc ccggccagca   2580
gctccacacc gcgcttgagg cccacgcccg ctgcccgggc cgccgcgccc agcccggacc   2640
```

gcagggactc ggcctcaccc ggcgccgccg gcggcctgga cccccaggac tccgcgcgct 2700
cgcgcctctc gtccaacttg tgaccctcgc cgaccgcccc gcgggcccag gcgggccagg 2760
ggcggggccg tcatccagac caaagccatg ccattgcgct gccccggccg ccagtccgcc 2820
cagaagccat agacgagacg taggtagccg tagttggacg gacgggcagg gccggcgggg 2880
cagccccctc cgcgcccccg gccgtccccc ctcatcgccc cgcgcccacc cccatcgccc 2940
ctgcccccgg cggcggcctc gcgtgcgagg gggctccctt cacctcggtg cctcagttcc 3000
cccagctgta agacagggac ggggcggccc agtggctgag aggagccggc tgtggagccc 3060
cgcccgcccc ccaccctcta ggtggccccc gtccgaggag gatcgttttc taagtgcaat 3120
acttggcccg ccggcttccc gctgccccca tcgcgctcac gcaataaccg gcccggcccc 3180
cgtccgcgcg cgtcccccgg tgacctcggg gagcagcacc ccgcctccct ccagcactgg 3240
caccgagggg caggcctggc tgcgcagggc gcggggggga ggctggggtc ccgccgccgt 3300
gatgaatgta ctgacgagcc gaggcagcag tgcccccacc gtggcccccc acgccccatt 3360
aacccccaca cccccattcc gcgcaataaa cgacagcatt ggcgccaaaa aaaaaaaaaa 3420
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 3459

<210> 4
<211> 889
<212> PRT
<213> Homo sapiens

<400> 4
Met Asp Ala Arg Gly Gly Gly Gly Arg Pro Gly Glu Ser Pro Gly Ala
1 5 10 15
Thr Pro Ala Pro Gly Pro Pro Pro Pro Pro Pro Pro Ala Pro Pro Gln
20 25 30
Gln Gln Pro Pro Pro Pro Pro Pro Pro Ala Pro Pro Pro Gly Pro Gly
35 40 45
Pro Ala Pro Pro Gln His Pro Pro Arg Ala Glu Ala Leu Pro Pro Glu
50 55 60
Ala Ala Asp Glu Gly Gly Pro Arg Gly Arg Leu Arg Ser Arg Asp Ser
65 70 75 80
Ser Cys Gly Arg Pro Gly Thr Pro Gly Ala Ala Ser Thr Ala Lys Gly
85 90 95
Ser Pro Asn Gly Glu Cys Gly Arg Gly Glu Pro Gln Cys Ser Pro Ala
100 105 110
Gly Pro Glu Gly Pro Ala Arg Gly Pro Lys Val Ser Phe Ser Cys Arg
115 120 125
Gly Ala Ala Ser Gly Pro Ala Pro Gly Pro Gly Pro Ala Glu Glu Ala
130 135 140
Gly Ser Glu Glu Ala Gly Pro Ala Gly Glu Pro Arg Gly Ser Gln Ala
145 150 155 160
Ser Phe Met Gln Arg Gln Phe Gly Ala Leu Leu Gln Pro Gly Val Asn
165 170 175
Lys Phe Ser Leu Arg Met Phe Gly Ser Gln Lys Ala Val Glu Arg Glu
180 185 190
Gln Glu Arg Val Lys Ser Ala Gly Ala Trp Ile Ile His Pro Tyr Ser
195 200 205

Asp Phe Arg Phe Tyr Trp Asp Phe Thr Met Leu Leu Phe Met Val Gly
    210   215   220

Asn Leu Ile Ile Ile Pro Val Gly Ile Thr Phe Phe Lys Asp Glu Thr
225   230   235   240

Thr Ala Pro Trp Ile Val Phe Asn Val Val Ser Asp Thr Phe Phe Leu
                245   250   255

Met Asp Leu Val Leu Asn Phe Arg Thr Gly Ile Val Ile Glu Asp Asn
            260   265   270

Thr Glu Ile Ile Leu Asp Pro Glu Lys Ile Lys Lys Lys Tyr Leu Arg
        275   280   285

Thr Trp Phe Val Val Asp Phe Val Ser Ser Ile Pro Val Asp Tyr Ile
    290   295   300

Phe Leu Ile Val Glu Lys Gly Ile Asp Ser Glu Val Tyr Lys Thr Ala
305   310   315   320

Arg Ala Leu Arg Ile Val Arg Phe Thr Lys Ile Leu Ser Leu Leu Arg
                325   330   335

Leu Leu Arg Leu Ser Arg Leu Ile Arg Tyr Ile His Gln Trp Glu Glu
            340   345   350

Ile Phe His Met Thr Tyr Asp Leu Ala Ser Ala Val Met Arg Ile Cys
        355   360   365

Asn Leu Ile Ser Met Met Leu Leu Leu Cys His Trp Asp Gly Cys Leu
    370   375   380

Gln Phe Leu Val Pro Met Leu Gln Asp Phe Pro Arg Asn Cys Trp Val
385   390   395   400

Ser Ile Asn Gly Met Val Asn His Ser Trp Ser Glu Leu Tyr Ser Phe
                405   410   415

Ala Leu Phe Lys Ala Met Ser His Met Leu Cys Ile Gly Tyr Gly Arg
            420   425   430

Gln Ala Pro Glu Ser Met Thr Asp Ile Trp Leu Thr Met Leu Ser Met
        435   440   445

Ile Val Gly Ala Thr Cys Tyr Ala Met Phe Ile Gly His Ala Thr Ala
    450   455   460

Leu Ile Gln Ser Leu Asp Ser Ser Arg Arg Gln Tyr Gln Glu Lys Tyr
465   470   475   480

Lys Gln Val Glu Gln Tyr Met Ser Phe His Lys Leu Pro Ala Asp Phe
                485   490   495

Arg Gln Lys Ile His Asp Tyr Tyr Glu His Arg Tyr Gln Gly Lys Met
            500   505   510

Phe Asp Glu Asp Ser Ile Leu Gly Glu Leu Asn Gly Pro Leu Arg Glu
        515   520   525

Glu Ile Val Asn Phe Asn Cys Arg Lys Leu Val Ala Ser Met Pro Leu
    530   535   540

Phe Ala Asn Ala Asp Pro Asn Phe Val Thr Ala Met Leu Thr Lys Leu
545   550   555   560

Lys Phe Glu Val Phe Gln Pro Gly Asp Tyr Ile Ile Arg Glu Gly Thr
                565   570   575

Ile Gly Lys Lys Met Tyr Phe Ile Gln His Gly Val Val Ser Val Leu

```
                580                 585                 590
Thr Lys Gly Asn Lys Glu Met Lys Leu Ser Asp Gly Ser Tyr Phe Gly
            595                 600                 605
Glu Ile Cys Leu Leu Thr Arg Gly Arg Arg Thr Ala Ser Val Arg Ala
    610                 615                 620
Asp Thr Tyr Cys Arg Leu Tyr Ser Leu Ser Val Asp Asn Phe Asn Glu
625                 630                 635                 640
Val Leu Glu Glu Tyr Pro Met Met Arg Arg Ala Phe Glu Thr Val Ala
                645                 650                 655
Ile Asp Arg Leu Asp Arg Ile Gly Lys Lys Asn Ser Ile Leu Leu His
            660                 665                 670
Lys Val Gln His Asp Leu Asn Ser Gly Val Phe Asn Asn Gln Glu Asn
        675                 680                 685
Ala Ile Ile Gln Glu Ile Val Lys Tyr Asp Arg Glu Met Val Gln Gln
    690                 695                 700
Ala Glu Leu Gly Gln Arg Val Gly Leu Phe Pro Pro Pro Pro Pro Pro
705                 710                 715                 720
Pro Gln Val Thr Ser Ala Ile Ala Thr Leu Gln Gln Ala Ala Ala Met
                725                 730                 735
Ser Phe Cys Pro Gln Val Ala Arg Pro Leu Val Gly Pro Leu Ala Leu
            740                 745                 750
Gly Ser Pro Arg Leu Val Arg Arg Pro Pro Pro Gly Pro Ala Pro Ala
        755                 760                 765
Ala Ala Ser Pro Gly Pro Pro Pro Pro Ala Ser Pro Pro Gly Ala Pro
    770                 775                 780
Ala Ser Pro Arg Ala Pro Arg Thr Ser Pro Tyr Gly Gly Leu Pro Ala
785                 790                 795                 800
Ala Pro Leu Ala Gly Pro Ala Leu Pro Ala Arg Arg Leu Ser Arg Ala
                805                 810                 815
Ser Arg Pro Leu Ser Ala Ser Gln Pro Ser Leu Pro His Gly Ala Pro
            820                 825                 830
Gly Pro Ala Ala Ser Thr Arg Pro Ala Ser Ser Ser Thr Pro Arg Leu
        835                 840                 845
Arg Pro Thr Pro Ala Ala Arg Ala Ala Ala Pro Ser Pro Asp Arg Arg
    850                 855                 860
Asp Ser Ala Ser Pro Gly Ala Ala Gly Gly Leu Asp Pro Gln Asp Ser
865                 870                 875                 880
Ala Arg Ser Arg Leu Ser Ser Asn Leu
                885
```

<210> 5
<211> 4751
<212> DNA
<213> Homo sapiens

<400> 5

```
tcgacaaaaa tgccagggaa aggcgagccc agagcttggt gatggagaaa ttgggaagcc        60
```

```
acccccccacc cttcaatctt aggatgggga attcgcaact gaagccggag cttcagactt    120
ggggcgcact cccagcttag cccaggaaag agatttaagg gcgcagcagt gtggatacct    180
ctcaccccgg ccccgaaggt ctagcgaggg tctaacctgg gccccttgcc aggcccgccc    240
cccgcccctt tccagccccc ggcccgtgcg ccgctgcccc tttaagaagc ccaggtaggc    300
aggcccggct gctggagccg ctcctatggc aacccgcgag ctgcggcggc ttcatgaata    360
ttccggggcg cgggagcccg agcgctgccg gagggcgctt cgggggaggc ggccgctgat    420
gtaagcccgg cgggtcgctg ggctccgctc ggttgcggcg ggagccccgg gacgggccgg    480
acgggccggg gcagaggagg cgaggcgagc tcgcgggtgg ccagccacaa agcccgggcg    540
gcgagacaga cggacagcca gccctcccgc gggacgcacg cccgggaccc gcgcgggccg    600
tgcgctctgc actccggagc ggttccctga gcgccgcggc cgcagagcct ctccggccgg    660
cgcccattgt tccccgcggg ggcggggcgc ctggagccgg gcggcgcgcc gcccctgaac    720
gccagaggga gggagggagg caagaaggga gcgcggggtc cccgcgccca gccgggcccg    780
ggaggaggtg tagcgcggcg agcccgggga ctcggagcgg gactaggatc ctccccgcgg    840
cgcgcagcct gcccaagcat gggcgcctga ggctgccccc acgccggcgg caaaggacgc    900
gtccccacgg gcggactgac cggcgggcgg acctggagcc cgtccgcggc gccgcgctcc    960
tgccccggc ccggtccgac cccggcccct ggcgccatgg acaagctgcc gccgtccatg   1020
cgcaagcggc tctacagcct cccgcagcag gtgggggcca aggcgtggat catggacgag   1080
gaagaggacg ccgaggagga gggggccggg ggccgccaag accccagccg caggagcatc   1140
cggctgcggc cactgccctc gccctccccc tcggcggccg cgggtggcac ggagtcccgg   1200
agctcggccc tcggggcagc ggacagcgaa gggccggccc gcggcgcggg caagtccagc   1260
acgaacggcg actgcaggcg cttccgcggg agcctggcct cgctgggcag ccggggcggc   1320
ggcacgggcg gcacggggag cggcagcagt cacggacacc tgcatgactc cgcggaggag   1380
cggcggctca tcgccgaggg cgacgcgtcc cccggcgagg acaggacgcc cccaggcctg   1440
gcggccgagc ccgagcgccc cggcgcctcg gcgcagcccg cagcctcgcc gccgccgccc   1500
cagcagccac cgcagccggc ctccgcctcc tgcgagcagc cctcggtgga caccgctatc   1560
aaagtggagg gaggcgcggc tgccggcgac cagatcctcc cggaggccga ggtgcgcctg   1620
ggccaggccg gcttcatgca gcgccagttc ggggccatgc tccaacccgg ggtcaacaaa   1680
ttctccctaa ggatgttcgg cagccagaaa gccgtggagc gcgaacagga gagggtcaag   1740
tcggccggat tttggattat ccacccctac agtgacttca gattttactg ggacctgacc   1800
atgctgctgc tgatggtggg aaacctgatt atcattcctg tgggcatcac cttcttcaag   1860
gatgagaaca ccacaccctg gattgtcttc aatgtggtgt cagacacatt cttcctcatc   1920
gacttggtcc tcaacttccg cacagggatc gtggtggagg acaacacaga gatcatcctg   1980
gacccgcagc ggattaaaat gaagtacctg aaaagctggt tcatggtaga tttcatttcc   2040
tccatccccg tggactacat cttcctcatt gtggagacac gcatcgactc ggaggtctac   2100
aagactgccc gggccctgcg cattgtccgc ttcacgaaga tcctcagcct cttacgcctg   2160
ttacgcctct cccgcctcat tcgatatatt caccagtggg aagagatctt ccacatgacc   2220
tacgacctgg ccagcgccgt ggtgcgcatc gtgaacctca tcggcatgat gctcctgctc   2280
tgccactggg acggctgcct gcagttcctg gtacccatgc tacaggactt ccctgacgac   2340
tgctgggtgt ccatcaacaa catggtgaac aactcctggg ggaagcagta ctcctacgcg   2400
ctcttcaagg ccatgagcca catgctgtgc atcggctacg ggcggcaggc gcccgtgggc   2460
atgtccgacg tctggctcac catgctcagc atgatcgtgg gtgccacctg ctacgccatg   2520
ttcattggcc acgccactgc cctcatccag tccctggact cctcccggcg ccagtaccag   2580
gaaaagtaca agcaggtgga gcagtacatg tcctttcaca agctcccgcc cgacacccgg   2640
cagcgcatcc acgactacta cgagcaccgc taccagggca agatgttcga cgaggagagc   2700
atcctgggcg agctaagcga gcccctgcgg gaggagatca tcaactttaa ctgtcggaag   2760
ctggtggcct ccatgccact gtttgccaat gcggacccca acttcgtgac gtccatgctg   2820
accaagctgc gtttcgaggt cttccagcct ggggactaca tcatccggga aggcaccatt   2880
```

```
ggcaagaaga tgtacttcat ccagcatggc gtggtcagcg tgctcaccaa gggcaacaag     2940
gagaccaagc tggccgacgg ctcctacttt ggagagatct gcctgctgac ccggggccgg     3000
cgcacagcca gcgtgagggc cgacacctac tgccgcctct actcgctgag cgtggacaac     3060
ttcaatgagg tgctggagga gtaccccatg atgcgaaggg ccttcgagac cgtggcgctg     3120
gaccgcctgg accgcattgg caagaagaac tccatcctcc tccacaaagt ccagcacgac     3180
ctcaactccg gcgtcttcaa ctaccaggag aatgagatca tccagcagat tgtgcagcat     3240
gaccgggaga tggcccactg cgcgcaccgc gtccaggctg ctgcctctgc caccccaacc     3300
cccacgcccg tcatctggac cccgctgatc caggcaccac tgcaggctgc cgctgccacc     3360
acttctgtgg ccatagccct cacccaccac cctcgcctgc ctgctgccat cttccgccct     3420
cccccaggat ctgggctggg caacctcggt gccgggcaga cgccaaggca cctgaaacgg     3480
ctgcagtccc tgatcccttc tgcgctgggc tccgcctcgc ccgccagcag cccgtcccag     3540
gtggacacac cgtcttcatc ctccttccac atccaacagc tggctggatt ctctgccccc     3600
gctggactga gcccactcct gccctcatcc agctcctccc caccccccgg ggcctgtggc     3660
tccccctcgg ctcccacacc atcagctggc gtagccgcca ccaccatagc cgggtttggc     3720
cacttccaca aggcgctggg tggctccctg tcctcctccg actctcccct gctcaccccg     3780
ctgcagccag gcgcccgctc cccgcaggct gcccagccat ctcccgcgcc acccggggcc     3840
cggggaggcc tgggactccc ggagcacttc ctgccacccc caccctcatc cagatccccg     3900
tcatctagcc ccgggcagct gggccagcct cccggggagt tgtccctagg tctggccact     3960
ggcccactga gcacgccaga gacaccccca cggcagcctg agccgccgtc ccttgtggca     4020
ggggcctctg ggggggcttc ccctgtaggc tttactcccc gaggaggtct cagcccccct     4080
ggccacagcc caggcccccc aagaaccttc ccgagtgccc cgccccgggc ctctggctcc     4140
cacggatcct tgctcctgcc acctgcatcc agccccccac caccccaggt cccccagcgc     4200
cggggcacac ccccgctcac ccccggccgc ctcacccagg acctcaagct catctccgcg     4260
tctcagccag ccctgcctca ggacggggcg cagactctcc gcagagcctc cccgcactcc     4320
tcaggggagt ccatggctgc cttcccgctc ttccccaggg ctgggggtgg cagcgggggc     4380
agtgggagca gcgggggcct cggtccccct gggaggccct atggtgccat ccccggccag     4440
cacgtcactc tgcctcggaa gacatcctca ggttctttgc cacccccctct gtctttgttt     4500
ggggcaagag ccacctcttc tgggggggccc cctctgactg ctggacccca gagggaacct     4560
ggggccaggc ctgagccagt gcgctccaaa ctgccgtcca atctatgagc tgggcccttc     4620
cttccctctt ctttcttctt ttctctccct tccttcttcc ttcaggttta actgtgatta     4680
ggagatatac caataacagt aataattatt taaaaaacca cacacaccag aaaaacaaaa     4740
gacagcagaa a                                                          4751
```

<210> 6

<211> 1203

<212> PRT

<213> Homo sapiens

<400> 6

```
Met Asp Lys Leu Pro Pro Ser Met Arg Lys Arg Leu Tyr Ser Leu Pro
1               5                   10                  15
Gln Gln Val Gly Ala Lys Ala Trp Ile Met Asp Glu Glu Glu Asp Ala
            20                  25                  30
Glu Glu Glu Gly Ala Gly Gly Arg Gln Asp Pro Ser Arg Arg Ser Ile
        35                  40                  45
Arg Leu Arg Pro Leu Pro Ser Pro Ser Pro Ser Ala Ala Ala Gly Gly
    50                  55                  60
```

```
Thr Glu Ser Arg Ser Ser Ala Leu Gly Ala Ala Asp Ser Glu Gly Pro
65                  70                  75                  80
Ala Arg Gly Ala Gly Lys Ser Ser Thr Asn Gly Asp Cys Arg Arg Phe
                85                  90                  95
Arg Gly Ser Leu Ala Ser Leu Gly Ser Arg Gly Gly Gly Thr Gly Gly
            100                 105                 110
Thr Gly Ser Gly Ser Ser His Gly His Leu His Asp Ser Ala Glu Glu
        115                 120                 125
Arg Arg Leu Ile Ala Glu Gly Asp Ala Ser Pro Gly Glu Asp Arg Thr
    130                 135                 140
Pro Pro Gly Leu Ala Ala Glu Pro Glu Arg Pro Gly Ala Ser Ala Gln
145                 150                 155                 160
Pro Ala Ala Ser Pro Pro Pro Pro Gln Gln Pro Pro Gln Pro Ala Ser
                165                 170                 175
Ala Ser Cys Glu Gln Pro Ser Val Asp Thr Ala Ile Lys Val Glu Gly
            180                 185                 190
Gly Ala Ala Ala Gly Asp Gln Ile Leu Pro Glu Ala Glu Val Arg Leu
        195                 200                 205
Gly Gln Ala Gly Phe Met Gln Arg Gln Phe Gly Ala Met Leu Gln Pro
    210                 215                 220
Gly Val Asn Lys Phe Ser Leu Arg Met Phe Gly Ser Gln Lys Ala Val
225                 230                 235                 240
Glu Arg Glu Gln Glu Arg Val Lys Ser Ala Gly Phe Trp Ile Ile His
                245                 250                 255
Pro Tyr Ser Asp Phe Arg Phe Tyr Trp Asp Leu Thr Met Leu Leu Leu
            260                 265                 270
Met Val Gly Asn Leu Ile Ile Ile Pro Val Gly Ile Thr Phe Phe Lys
        275                 280                 285
Asp Glu Asn Thr Thr Pro Trp Ile Val Phe Asn Val Val Ser Asp Thr
    290                 295                 300
Phe Phe Leu Ile Asp Leu Val Leu Asn Phe Arg Thr Gly Ile Val Val
305                 310                 315                 320
Glu Asp Asn Thr Glu Ile Ile Leu Asp Pro Gln Arg Ile Lys Met Lys
                325                 330                 335
Tyr Leu Lys Ser Trp Phe Met Val Asp Phe Ile Ser Ser Ile Pro Val
            340                 345                 350
Asp Tyr Ile Phe Leu Ile Val Glu Thr Arg Ile Asp Ser Glu Val Tyr
        355                 360                 365
Lys Thr Ala Arg Ala Leu Arg Ile Val Arg Phe Thr Lys Ile Leu Ser
    370                 375                 380
Leu Leu Arg Leu Leu Arg Leu Ser Arg Leu Ile Arg Tyr Ile His Gln
385                 390                 395                 400
Trp Glu Glu Ile Phe His Met Thr Tyr Asp Leu Ala Ser Ala Val Val
                405                 410                 415
Arg Ile Val Asn Leu Ile Gly Met Met Leu Leu Leu Cys His Trp Asp
            420                 425                 430
Gly Cys Leu Gln Phe Leu Val Pro Met Leu Gln Asp Phe Pro Asp Asp
```

```
        435                 440                 445
Cys Trp Val Ser Ile Asn Asn Met Val Asn Asn Ser Trp Gly Lys Gln
    450                 455                 460
Tyr Ser Tyr Ala Leu Phe Lys Ala Met Ser His Met Leu Cys Ile Gly
465                 470                 475                 480
Tyr Gly Arg Gln Ala Pro Val Gly Met Ser Asp Val Trp Leu Thr Met
                485                 490                 495
Leu Ser Met Ile Val Gly Ala Thr Cys Tyr Ala Met Phe Ile Gly His
            500                 505                 510
Ala Thr Ala Leu Ile Gln Ser Leu Asp Ser Ser Arg Arg Gln Tyr Gln
        515                 520                 525
Glu Lys Tyr Lys Gln Val Glu Gln Tyr Met Ser Phe His Lys Leu Pro
    530                 535                 540
Pro Asp Thr Arg Gln Arg Ile His Asp Tyr Tyr Glu His Arg Tyr Gln
545                 550                 555                 560
Gly Lys Met Phe Asp Glu Glu Ser Ile Leu Gly Glu Leu Ser Glu Pro
                565                 570                 575
Leu Arg Glu Glu Ile Ile Asn Phe Asn Cys Arg Lys Leu Val Ala Ser
            580                 585                 590
Met Pro Leu Phe Ala Asn Ala Asp Pro Asn Phe Val Thr Ser Met Leu
        595                 600                 605
Thr Lys Leu Arg Phe Glu Val Phe Gln Pro Gly Asp Tyr Ile Ile Arg
    610                 615                 620
Glu Gly Thr Ile Gly Lys Lys Met Tyr Phe Ile Gln His Gly Val Val
625                 630                 635                 640
Ser Val Leu Thr Lys Gly Asn Lys Glu Thr Lys Leu Ala Asp Gly Ser
                645                 650                 655
Tyr Phe Gly Glu Ile Cys Leu Leu Thr Arg Gly Arg Arg Thr Ala Ser
            660                 665                 670
Val Arg Ala Asp Thr Tyr Cys Arg Leu Tyr Ser Leu Ser Val Asp Asn
        675                 680                 685
Phe Asn Glu Val Leu Glu Glu Tyr Pro Met Met Arg Arg Ala Phe Glu
    690                 695                 700
Thr Val Ala Leu Asp Arg Leu Asp Arg Ile Gly Lys Lys Asn Ser Ile
705                 710                 715                 720
Leu Leu His Lys Val Gln His Asp Leu Asn Ser Gly Val Phe Asn Tyr
                725                 730                 735
Gln Glu Asn Glu Ile Ile Gln Gln Ile Val Gln His Asp Arg Glu Met
            740                 745                 750
Ala His Cys Ala His Arg Val Gln Ala Ala Ala Ser Ala Thr Pro Thr
        755                 760                 765
Pro Thr Pro Val Ile Trp Thr Pro Leu Ile Gln Ala Pro Leu Gln Ala
    770                 775                 780
Ala Ala Ala Thr Thr Ser Val Ala Ile Ala Leu Thr His His Pro Arg
785                 790                 795                 800
Leu Pro Ala Ala Ile Phe Arg Pro Pro Pro Gly Ser Gly Leu Gly Asn
                805                 810                 815
```

Leu Gly Ala Gly Gln Thr Pro Arg His Leu Lys Arg Leu Gln Ser Leu
820 825 830

Ile Pro Ser Ala Leu Gly Ser Ala Ser Pro Ala Ser Ser Pro Ser Gln
835 840 845

Val Asp Thr Pro Ser Ser Ser Ser Phe His Ile Gln Gln Leu Ala Gly
850 855 860

Phe Ser Ala Pro Ala Gly Leu Ser Pro Leu Leu Pro Ser Ser Ser Ser
865 870 875 880

Ser Pro Pro Pro Gly Ala Cys Gly Ser Pro Ser Ala Pro Thr Pro Ser
885 890 895

Ala Gly Val Ala Ala Thr Thr Ile Ala Gly Phe Gly His Phe His Lys
900 905 910

Ala Leu Gly Gly Ser Leu Ser Ser Ser Asp Ser Pro Leu Leu Thr Pro
915 920 925

Leu Gln Pro Gly Ala Arg Ser Pro Gln Ala Ala Gln Pro Ser Pro Ala
930 935 940

Pro Pro Gly Ala Arg Gly Gly Leu Gly Leu Pro Glu His Phe Leu Pro
945 950 955 960

Pro Pro Pro Ser Ser Arg Ser Pro Ser Ser Ser Pro Gly Gln Leu Gly
965 970 975

Gln Pro Pro Gly Glu Leu Ser Leu Gly Leu Ala Thr Gly Pro Leu Ser
980 985 990

Thr Pro Glu Thr Pro Pro Arg Gln Pro Glu Pro Pro Ser Leu Val Ala
995 1000 1005

Gly Ala Ser Gly Gly Ala Ser Pro Val Gly Phe Thr Pro Arg Gly Gly
1010 1015 1020

Leu Ser Pro Pro Gly His Ser Pro Gly Pro Pro Arg Thr Phe Pro Ser
1025 1030 1035 104

Ala Pro Pro Arg Ala Ser Gly Ser His Gly Ser Leu Leu Leu Pro Pro
1045 1050 1055

Ala Ser Ser Pro Pro Pro Pro Gln Val Pro Gln Arg Arg Gly Thr Pro
1060 1065 1070

Pro Leu Thr Pro Gly Arg Leu Thr Gln Asp Leu Lys Leu Ile Ser Ala
1075 1080 1085

Ser Gln Pro Ala Leu Pro Gln Asp Gly Ala Gln Thr Leu Arg Arg Ala
1090 1095 1100

Ser Pro His Ser Ser Gly Glu Ser Met Ala Ala Phe Pro Leu Phe Pro
1105 1110 1115 112

Arg Ala Gly Gly Gly Ser Gly Gly Ser Gly Ser Ser Gly Gly Leu Gly
1125 1130 1135

Pro Pro Gly Arg Pro Tyr Gly Ala Ile Pro Gly Gln His Val Thr Leu
1140 1145 1150

Pro Arg Lys Thr Ser Ser Gly Ser Leu Pro Pro Pro Leu Ser Leu Phe
1155 1160 1165

Gly Ala Arg Ala Thr Ser Ser Gly Gly Pro Pro Leu Thr Ala Gly Pro
1170 1175 1180

Gln Arg Glu Pro Gly Ala Arg Pro Glu Pro Val Arg Ser Lys Leu Pro

1185 1190 1195 120
Ser Asn Leu

<210> 7
<211> 3496
<212> DNA
<213> Homo sapiens

<400> 7
gaaatcgagc aggagcgggt gaagtcagcg ggggcctgga tcatccaccc ctacagcgac 60
ttccggtttt actgggacct gatcatgctg ctgctgatgg tggggaacct catcgtcctg 120
cctgtgggca tcaccttctt caaggaggag aactccccgc cttggatcgt cttcaacgta 180
ttgtctgata ctttcttcct actggatctg gtgctcaact tccgaacggg catcgtggtg 240
gaggagggtg ctgagatcct gctggcaccg cgggccatcc gcacgcgcta cctgcgcacc 300
tggttcctgg ttgacctcat ctcttctatc cctgtggatt acatcttcct agtggtggag 360
ctggagccac ggttggacgc tgaggtctac aaaacggcac gggccctacg catcgttcgc 420
ttcaccaaga tcctaagcct gctgaggctg ctccgcctct cccgcctcat ccgctacata 480
caccagtggg aggagatctt tcacatgacc tatgacctgg ccagtgctgt ggttcgcatc 540
ttcaacctca ttgggatgat gctgctgcta tgtcactggg atggctgtct gcagttcctg 600
gtgcccatgc tgcaggactt ccctcccgac tgctgggtct ccatcaacca catggtgaac 660
cactcgtggg gccgccagta ttcccatgcc ctgttcaagg ccatgagcca catgctgtgc 720
attggctatg ggcagcaggc acctgtaggc atgcccgacg tctggctcac catgctcagc 780
atgatcgtag gtgccacatg ctacgccatg ttcatcggcc atgccacggc actcatccag 840
tccctggact cttccccggcg tcagtaccag gagaagtaca agcaggtgga gcagtacatg 900
tccttccaca agctgccagc agacacgcgg cagcgcatcc acgagtacta tgagcaccgc 960
taccagggca agatgttcga tgaggaaagc atcctgggcg agctgagcga gccgcttcgc 1020
gaggagatca ttaacttcac ctgtcggggc ctggtggccc acatgccgct gtttgcccat 1080
gccgacccca gcttcgtcac tgcagttctc accaagctgc gctttgaggt cttccagccg 1140
ggggatctcg tggtgcgtga gggctccgtg gggaggaaga tgtacttcat ccagcatggg 1200
ctgctcagtg tgctggcccg cggcgcccgg gacacacgcc tcaccgatgg atcctacttt 1260
ggggagatct gcctgctaac taggggccgg cgcacagcca gtgttcgggc tgacacctac 1320
tgccgccttt actcactcag cgtggaccat ttcaatgctg tgcttgagga gttccccatg 1380
atgcgccggg cctttgagac tgtggccatg gatcggctgc tccgcatcgg caagaagaat 1440
tccatactgc agcggaagcg ctccgagcca agtccaggca gcagtggtgg catcatggag 1500
cagcacttgg tgcaacatga cagagacatg gctcggggtg ttcggggtcg ggccccgagc 1560
acaggagctc agcttagtgg aaagccagta ctgtgggagc cactggtaca tgcgcccctt 1620
caggcagctg ctgtgacctc caatgtggcc attgccctga ctcatcagcg ggccctctg 1680
cccctctccc ctgactctcc agccaccctc cttgctcgct ctgcttggcg ctcagcaggc 1740
tctccagctt ccccgctggt gcccgtccga gctggcccat gggcatccac ctcccgcctg 1800
cccgccccac ctgcccgaac cctgcacgcc agcctatccc gggcagggcg ctcccaggtc 1860
tccctgctgg gtccccctcc aggaggaggt ggacggcggc taggacctcg ggccgcccca 1920
ctctcagcct cccaaccctc tctgcctcag cgggcaacag gcgatggctc tcctgggcgt 1980
aagggatcag gaagtgagcg gctgcctccc tcagggctcc tggccaaacc tccaaggaca 2040
gcccagcccc ccaggccacc agtgcctgag ccagccacac cccggggtct ccagctttct 2100
gccaacatgt aaaacctttg agtacatcca gccttagttc ttggggtgca gtagtatgta 2160
cccaagggca gatgcctctt ggggaaggcc atggggacct gaaacattgc cccatggaaa 2220

```
tgtcgaccct gtgcggacat tccgcatact gccatgaaga cggtctctgt gtcctcagct     2280
caagaatcct gtagcttgtc ccatcataat ccattcaccc gttcatcatg tgtactgagc     2340
agctaccatg ttcaaggtaa tatgccaggc gctgtatgtc tccactgcca agtagaagtg     2400
actcaaaacc ctctgacaag gatattccct tggctatggt cctgccaggt gcaggcccag     2460
gcccatgacc ccacctttac taagcacaag tacttgccac tgccatcact gccaagtaac     2520
tagatgtctc tgtttccctg ccaatgatcc tgcaggttct gcccggtctg gttatcttcc     2580
tgttcctgta gcatagccag gcactgccag tcacctgtgc cccattgct  gtcagcagat     2640
gtcttgggtc ctgagtgtgg gtatccactt ttacccgctc actgccacct gtggacactc     2700
tgtgtctacc ctctgagtgg gaacatactt ctaagttccc tgcagtctct gtcctgtggt     2760
agaccatctt tttgtaaact gcgagcttcc tcttccctgt accctctgcc ccagtcgtga     2820
ccccctaaaa gttaaggggt agttggcacc tccttattaa tatgccagcc tagatccccc     2880
ccggtggagg ggcaaatggc tgaatccttg tgtgatattt ttttcttcgc ttgtttattt     2940
attcatttat ttaattgtat ttattcattt actaacttta tgtgttacca attaattttg     3000
tttacccatt cctttatcca tccctcccct ccttttcagg taaggagaca ggaggagtag     3060
gaggaggcag ggcctctcca tgccagcctc tgtggtcctt gcccaaaccc atcagcgcaa     3120
tacttgaacc ttctcccagg taggggcagg aggagccaca tgagagaggg agaaggaccg     3180
cgtttacctt tagagttttg ttttgttttt tccttctgag tttgctgttg gtgcaggaat     3240
aagggaaagg cccaaggtat ccaagcctgg ggaagggcag gccagccagc acctctgcct     3300
tctcagggac aagagtagtc ctttaccacc ctcactctgc ctgtcccctc tcctactcta     3360
cagcattaaa gactgtggga ccaggaccct aagtctcctt tccttctggg tggggagttc     3420
tggggttctt ggtgtgtggg agaagtttta taattgcttc caaacagctg ggtttaaata     3480
taaaatagac acactc                                                     3496
```

<210> 8

<211> 703

<212> PRT

<213> Homo sapiens

<400> 8

```
Glu Ile Glu Gln Glu Arg Val Lys Ser Ala Gly Ala Trp Ile Ile His
1               5                   10                  15
Pro Tyr Ser Asp Phe Arg Phe Tyr Trp Asp Leu Ile Met Leu Leu Leu
            20                  25                  30
Met Val Gly Asn Leu Ile Val Leu Pro Val Gly Ile Thr Phe Phe Lys
        35                  40                  45
Glu Glu Asn Ser Pro Pro Trp Ile Val Phe Asn Val Leu Ser Asp Thr
    50                  55                  60
Phe Phe Leu Leu Asp Leu Val Leu Asn Phe Arg Thr Gly Ile Val Val
65                  70                  75                  80
Glu Glu Gly Ala Glu Ile Leu Leu Ala Pro Arg Ala Ile Arg Thr Arg
                85                  90                  95
Tyr Leu Arg Thr Trp Phe Leu Val Asp Leu Ile Ser Ser Ile Pro Val
            100                 105                 110
Asp Tyr Ile Phe Leu Val Val Glu Leu Glu Pro Arg Leu Asp Ala Glu
        115                 120                 125
Val Tyr Lys Thr Ala Arg Ala Leu Arg Ile Val Arg Phe Thr Lys Ile
    130                 135                 140
```

```
Leu Ser Leu Leu Arg Leu Leu Arg Leu Ser Arg Leu Ile Arg Tyr Ile
145                 150                 155                 160
His Gln Trp Glu Glu Ile Phe His Met Thr Tyr Asp Leu Ala Ser Ala
                165                 170                 175
Val Val Arg Ile Phe Asn Leu Ile Gly Met Met Leu Leu Leu Cys His
            180                 185                 190
Trp Asp Gly Cys Leu Gln Phe Leu Val Pro Met Leu Gln Asp Phe Pro
        195                 200                 205
Pro Asp Cys Trp Val Ser Ile Asn His Met Val Asn His Ser Trp Gly
    210                 215                 220
Arg Gln Tyr Ser His Ala Leu Phe Lys Ala Met Ser His Met Leu Cys
225                 230                 235                 240
Ile Gly Tyr Gly Gln Gln Ala Pro Val Gly Met Pro Asp Val Trp Leu
                245                 250                 255
Thr Met Leu Ser Met Ile Val Gly Ala Thr Cys Tyr Ala Met Phe Ile
            260                 265                 270
Gly His Ala Thr Ala Leu Ile Gln Ser Leu Asp Ser Ser Arg Arg Gln
        275                 280                 285
Tyr Gln Glu Lys Tyr Lys Gln Val Glu Gln Tyr Met Ser Phe His Lys
    290                 295                 300
Leu Pro Ala Asp Thr Arg Gln Arg Ile His Glu Tyr Tyr Glu His Arg
305                 310                 315                 320
Tyr Gln Gly Lys Met Phe Asp Glu Glu Ser Ile Leu Gly Glu Leu Ser
                325                 330                 335
Glu Pro Leu Arg Glu Glu Ile Ile Asn Phe Thr Cys Arg Gly Leu Val
            340                 345                 350
Ala His Met Pro Leu Phe Ala His Ala Asp Pro Ser Phe Val Thr Ala
        355                 360                 365
Val Leu Thr Lys Leu Arg Phe Glu Val Phe Gln Pro Gly Asp Leu Val
    370                 375                 380
Val Arg Glu Gly Ser Val Gly Arg Lys Met Tyr Phe Ile Gln His Gly
385                 390                 395                 400
Leu Leu Ser Val Leu Ala Arg Gly Ala Arg Asp Thr Arg Leu Thr Asp
                405                 410                 415
Gly Ser Tyr Phe Gly Glu Ile Cys Leu Leu Thr Arg Gly Arg Arg Thr
            420                 425                 430
Ala Ser Val Arg Ala Asp Thr Tyr Cys Arg Leu Tyr Ser Leu Ser Val
        435                 440                 445
Asp His Phe Asn Ala Val Leu Glu Glu Phe Pro Met Met Arg Arg Ala
    450                 455                 460
Phe Glu Thr Val Ala Met Asp Arg Leu Leu Arg Ile Gly Lys Lys Asn
465                 470                 475                 480
Ser Ile Leu Gln Arg Lys Arg Ser Glu Pro Ser Pro Gly Ser Ser Gly
                485                 490                 495
Gly Ile Met Glu Gln His Leu Val Gln His Asp Arg Asp Met Ala Arg
            500                 505                 510
Gly Val Arg Gly Arg Ala Pro Ser Thr Gly Ala Gln Leu Ser Gly Lys
```

```
        515                 520                 525
Pro Val Leu Trp Glu Pro Leu Val His Ala Pro Leu Gln Ala Ala Ala
    530                 535                 540
Val Thr Ser Asn Val Ala Ile Ala Leu Thr His Gln Arg Gly Pro Leu
545                 550                 555                 560
Pro Leu Ser Pro Asp Ser Pro Ala Thr Leu Leu Ala Arg Ser Ala Trp
                565                 570                 575
Arg Ser Ala Gly Ser Pro Ala Ser Pro Leu Val Pro Val Arg Ala Gly
            580                 585                 590
Pro Trp Ala Ser Thr Ser Arg Leu Pro Ala Pro Pro Ala Arg Thr Leu
        595                 600                 605
His Ala Ser Leu Ser Arg Ala Gly Arg Ser Gln Val Ser Leu Leu Gly
    610                 615                 620
Pro Pro Pro Gly Gly Gly Gly Arg Arg Leu Gly Pro Arg Gly Arg Pro
625                 630                 635                 640
Leu Ser Ala Ser Gln Pro Ser Leu Pro Gln Arg Ala Thr Gly Asp Gly
                645                 650                 655
Ser Pro Gly Arg Lys Gly Ser Gly Ser Glu Arg Leu Pro Pro Ser Gly
            660                 665                 670
Leu Leu Ala Lys Pro Pro Arg Thr Ala Gln Pro Pro Arg Pro Pro Val
        675                 680                 685
Pro Glu Pro Ala Thr Pro Arg Gly Leu Gln Leu Ser Ala Asn Met
    690                 695                 700
```

<210> 9
<211> 18
<212> DNA
<213> Homo sapiens

<400> 9
ggccatgctg accaagct 18

<210> 10
<211> 18
<212> DNA
<213> Homo sapiens

<400> 10
gtgccttcgc ggatgatg 18

<210> 11
<211> 22
<212> DNA
<213> Homo sapiens

<400> 11
tcacccggct ggaagacctc ga 22

<210> 12
<211> 23
<212> DNA
<213> Homo sapiens

<400> 12
tgagacagca gatagagcca agc 23

<210> 13
<211> 22
<212> DNA
<213> Homo sapiens

<400> 13
tccctgccaa tttgacatct tc 22

<210> 14
<211> 26
<212> DNA
<213> Homo sapiens

<400> 14
catcaccatt ggcaatgagc ggttcc 26

<210> 15
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> RDA primer

<400> 15
agcactctcc agcctctcac cgca 24

<210> 16
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> RDA primer

<400> 16
gatctgcggt ga 12

<210> 17
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> RDA primer

<400> 17
accgacgtcg actatccatg aaca 24

<210> 18
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> RDA primer

<400> 18
gatctgttca tg 12

<210> 19
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> RDA primer

<400> 19
aggcaactgt gctatccgag ggaa 24

<210> 20
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> RDA primer

<400> 20
gatcttccct cg 12

<210> 21
<211> 54
<212> DNA

<213> Artificial Sequence

<220>
<223> SSH adapter oligonucleotide

<400> 21
ctaatacgac tcactatagg gctcgagcgg ccgcccgggc aggtacctgc ccgg 54

<210> 22
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> SSH adapter oligonucleotide

<400> 22
ctaatacgac tcactatagg gcagcgtggt cgcggccgag gtacctcggc cg 52

<210> 23
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 23
ctaatacgac tcactatagg gc 22

<210> 24
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR nested primer

<400> 24
tcgagcggcc gcccgggcag gt 22

<210> 25
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

<223> PCR primer

<400> 25
ctaatacgac tcactatagg gc 22

<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR nested primer

<400> 26
agcgtggtcg cggccgaggt 20